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CAGING CARBON MONOXIDE FOR THERAPEUTIC APPLICATIONS AND
CARBONYLATION REACTIONS

by

LADIE KIMBERLY DE LA CRUZ

Under the Direction of Binghe Wang, PhD

ABSTRACT
Carbon monoxide (CO) is formed endogenously and plays various essential physiological
and therapeutic functions. In the field of organic synthesis, CO is an important C1 synthon for
building complex molecules. However, delivery of CO in the gaseous form presents challenges
such as toxicity, storage, and dosage control. Therefore, there is considerable research interest in
the development of approaches to cage CO in a form that is easier to store, handle, and deliver.
Various chemical strategies to cage CO for therapeutic and synthetic applications are described
herein.
Because of its pleiotropic effects, CO is a good candidate for combination therapy. A
prodrug strategy that relies on a three-reaction cascade leading to the release of more than one drug

component with the generation of a fluorescent side product for easy monitoring was developed.
As a proof of concept, co-delivery of CO with the antibiotic metronidazole was demonstrated. The
utility of this strategy was demonstrated in an in vitro model wherein administration of the cascade
prodrug led to 26-fold sensitization of H. pylori against metronidazole.
With the goal of achieving pharmaceutically viable “CO in a pill”, we developed a new
class of CO prodrugs that is based on benign carriers that have well-established safety profiles.
With CO caged in a dicarbonyl moiety, we attached FDA-approved non-calorific sweeteners as
the leaving groups. This ensemble cages CO in a stable prodrug that relies on hydrolysis to deliver
CO. This CO prodrug recapitulated anti-inflammatory effects of CO against LPS-induced TNF-𝛼
production. Furthermore, oral administration of the prodrug led to an elevation of COHb in mice
indicating its pharmaceutical viability as a CO prodrug.
We developed a visible light-activated CO donor/surrogate for carbonylation reaction. This
solid CO reagent is easily synthesized from readily available starting materials, stable under
ambient light, requires readily available low-power blue LED for activation, and releases two
equivalents of CO. Using this donor, a simple, one-pot, glovebox-free protocol was successfully
implemented in conventional palladium-catalyzed carbonylative transformations. Distinctively,
this CO donor has been shown to be especially compatible with light-assisted carbonylation of
conventionally inaccessible substrates such as alkyl halides and bulky nucleophiles.

INDEX WORDS: Carbon Monoxide Prodrugs, Cascade Prodrug, Click chemistry, CO
Surrogate, Photosensitive CO donors, Pd-catalyzed Carbonylation
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CLICK, RELEASE, AND FLUORESCE: A CHEMICAL STRATEGY FOR A

CASCADE PRODRUG SYSTEM FOR CO-DELIVERY OF CARBON MONOXIDE,
A DRUG PAYLOAD AND A FLUORESCENT REPORTER
1.1

Introduction
1.1.1

Drug Combination Therapy

Combination therapy is a method of treatment involving the co-administration of multiple
therapeutic agents. This treatment modality has been shown to be effective against cancer, bacterial
and viral infections, neurodegenerative, and vascular diseases. For example, in treating HIV,
cocktails of HIV protease inhibitor and/or reverse transcriptase inhibitors1 have shown remarkable
effects. In the area of antibacterials, the use of Augmentin, which combines a -lactam antibiotic
with a -lactamase inhibitor,2 allows for the effective control of infections by drug resistant strains
of bacteria. Another example is the administration of a hybrid compound of sulfonamide and
dihydrofolate reductase inhibitor to achieve inhibition of two enzymes on the same biosynthetic
pathway leading to folic acid, which is important for bacterial survival.3 In certain cases such as
early mitigation of hypertension, combination therapy provides advantages compared to
monotherapy.4

What makes combination therapy effective relative to monotherapy? Co-

administration of two or more agents allows for engagement of multiple targets which can
potentially slow down development of drug resistance, and lower the required therapeutic dose for
each component.5 Challenges to look out for include, compounded toxicity of each of the
components and amplification of side effects,6 and pharmacokinetic and pharmacodynamic
interactions.7
Herein we explore the idea of using prodrug approaches to deliver multiple components
from a single chemical entity, with the aim of improved pharmacokinetic control and ease of
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administration. In appropriate situations, such an approach will be very useful. In demonstrating
the proof of concept, we select the delivery of carbon monoxide (CO) and model drug payloads the antibiotic metronidazole and the anticancer drug podophyllotoxin.
1.1.2

Carbon Monoxide as an Anti-Cancer and Anti-Bacterial Agent

Despite being notorious for its toxicity at high concentration, CO has recently been in the
spotlight for its promising potential as a medical gas.8-10 It is produced endogenously in the human
body from the degradation of heme by heme-oxygenase.11 The discovery that CO, like nitric oxide
(NO), activates soluble guanylate cyclase12 was a milestone in understanding the physiological
relevance of CO and in triggering an ever-increasing level of research interest in this area.13 Since
then, mounting evidence from a multitude of studies have demonstrated that both endogenously
produced and exogenously introduced CO plays important roles in inflammation,14,15 cell
proliferation,16 and cellular response to pathogens17,18 among other effects. Safety concerns have
been addressed by human safety trials wherein it was shown that CO inhalation of 500 ppm for 1
h is well-tolerated in healthy subjects – that is CO-bound hemoglobin did not increase to more
than 10% and there were no adverse events observed in the course of the experiments.19 Due to
convincing pre-clinical studies, CO gas is now in several clinical trials such as for treatment of
idiopathic pulmonary fibrosis (ClinicalTrials.Gov identifier: NCT01214187) and for severe
pulmonary arterial hypertension (ClinicalTrials.Gov identifier: NCT01523548).
1.1.2.1

Anti-Cancer Effects of CO

The CO/HO-1 system has been shown to offer protective effects in primary cells and
organs for transplantation as HO-1 is considered to be a cytoprotective gene. For example,
cytoprotection was observed in pancreatic islets β-cells upon overexpression of HO-1, and was
likewise observed with exogenous, pre-exposure, treatment of CO alone.20 Protection was
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mediated through CO’s antiapoptotic action via activation of cyclic GMP-dependent protein
kinases. Furthermore, CO’s anti-inflammatory effects, either through cGMP, NO, and MAPK
pathway, also contributes to the observed cytoprotection.15,21,22 In direct divergence to the
aforementioned cytoprotective effects, CO has been shown to be antiproliferative to tumors.23-25
In 2013, CO was demonstrated to magnify prostate cancer cell susceptibility to chemotherapeutic
agents such as doxorubicin or camptothecin.23 This was attributed to CO-mediated anti-Warburg
effect wherein cancer cells, because of their highly glycolytic phenotype, are driven to metabolic
exhaustion by exposure to CO.
1.1.2.2

Antibacterial Effects of CO

In the food industry, modified atmosphere packaging with CO (around 0.4%) keeps meat
looking fresh due to prevention of surface discoloration, prevents the development of off-odors,26
and lengthens the shelf-life through its antimicrobial properties27. Meat pathogens such as E. coli
015728,29, pathogenic Salmonella29, Listeria monocytogenes30, and Yersinia enterocolitica30 were
all reported to be inhibited by 0.4% CO-modified atmosphere packaging. As early as 1980, the
selective antibacterial effects of CO were shown in a study wherein 30% CO modified atmosphere
did not inhibit growth of P. aeruginosa, while growth inhibition was observed in E. coli.31
Some microbes relevant to human health have also been reported to be susceptible towards
either HO-1/CO or CORMs. Induction of HO-1 by CoPP or exposure to CO through ALF186
increased the intestinal macrophage bacterial clearance of E. coli, E. faecalis and S. typhimurium.32
Mycobacterium tuberculosis stimulates HO-1 in host macrophage and the generated CO compels
the bacteria to go into dormancy without killing the bacteria.33
One major school of thought regarding CO’s antimicrobial activity identifies the HO-1/CO
pathway as a means to amplify host innate response that will ultimately clear the pathogen through
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enhanced phagocytosis.34-36 In sepsis, HO-1 deficiency decreases survival while HO-1
overexpression improves bacterial clearance and survival. Further studies reveals that
macrophage-generated CO stimulates the bacteria to produce and release ATP which then binds
to macrophage nucleotide P2 receptors leading to the activation of the NALP3/IL-1β
inflammasome.36
Exogenous source of CO that have been widely used in many studies are metal containing
CO releasing molecules. CORM-1 reduces the viable cell counts of biofilm-embedded
Staphylococcus aureus.37 A photoCORM mediates the killing of an antibiotic resistant strain E.
coli EC958, while mildly potentiating the antimicrobial effect of doxycycline.38 CORM-2
exposure for 4 h reduces bacterial counts of around 2.5 log units of a uropathogenic E. coli strain.39
CORM-2 and CORM-3 inhibits the viability of H. pylori 26695 by 4-logs and 2-logs
respectively.17 CORM-3 reduces the bacterial count of Pseudomonas aeruginosa by 4-logs.40
CORM-2 (MIC = 10 µM) prevents biofilm maturation, is toxic against Pseudomonas aeruginosa,
and works additively with the antibiotic tobramycin.41 TryptoCORM, a photoactivatable CORM,
kills >99% of Neisseria gonorrhoeae even in the absence of light.42
Because CO is known to interact strongly with transition metals, the other prevailing
thought regarding CO’s antimicrobial activity points at the direct interaction of CO with bacterial
targets such as the mitochondrial electron transport chain leading to ATP depletion, and inhibition
of other transition-metal containing proteins essential to cellular operations.43 However, most of
the exogenous CO donors used in these studies were transition-metal containing CORMs whose
biological activities are complicated by an extensive solution chemistry

44-46

. Ru-carbonyl

CORMs, exemplified by CORM-3 exhibit the most potent antimicrobial effects against
Escherichia coli. However, in buffers and cell culture, CORM-3 releases little CO and the active
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antimicrobial agent is Ru(II), which binds tightly to thiols 47. As a result, thiols and amino acids in
complex growth media – such as histidine, methionine and oxidized glutathione, but especially
cysteine and reduced glutathione (GSH) – protect both bacterial and mammalian cells against
CORM-3 by binding and sequestering Ru(II). NMR reveals that CORM-3 binds cysteine and GSH
in a 1:1 stoichiometry with dissociation constants, Kd, of about 5 μM. Indeed, there is a direct
positive correlation between protection and amino acid affinity for CORM-3

47

. Therefore,

intracellular targets of CORM-3 in both bacterial and mammalian cells are expected to include
GSH, free Cys, His and Met residues and any molecule that contain these surface-exposed amino
acids. These results should prompt a major reappraisal of the biological effects of CORM-3 and
related CORMs.
1.1.3

Organic “click and release” CO prodrug strategy

Aside from direct inhalation, other routes of CO administration involve the use of metalbased CO releasing molecules (CO-RMs)48-56 including photo-CORMs,57-64 boranocarbonate and
its derivatives,65 photosensitive organic CO-RMs66-69 and hemoglobin-based CO carrier.70,71
Adding to this list of CO gas surrogates are a group of recently reported organic CO prodrugs.7277

Generally speaking, the design of such organic CO-prodrugs takes advantage of an

intramolecular cycloaddition reaction between a dienone and an alkyne to form a bicyloheptenone
intermediate that spontaneously undergoes a cheletropic reaction to extrude CO. The ability of this
prodrug system to supply CO and to exert its biological effects has been demonstrated through the
inhibition of LPS-induced TNF- secretion in RAW 264.7 cells, and attenuation of 2,4,6trinitrobenzensulfonic acid (TNBS)-induced experimental colitis in mice.72-77
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1.1.4

Design of CO cascade prodrug for combination therapy

Pushing forward and building on the flexibility of the design of this click-and-release
organic scaffold, we were interested in exploring the possibility of coupling the release of CO to
another drug payload for potential multi-drug therapy applications (Fig 1.1). The other two
gasotransmitters, nitric oxide and hydrogen sulfide, have been conjugated to compatible
therapeutic agents such as anticancer, cytototoxic, and anti-inflammatory drugs to expand the
therapeutic scope of these gases.78,79 Based on previous reports of CO’s ability to work additively
and/or synergistically with other entities such as cytotoxic agents (doxorubicin),80 antibiotics
(metronidazole),17 and anti-inflammatory agents,81 we sought to develop a platform where
compatible drugs can be easily conjugated to our previously developed CO releasing scaffold.75
By combining a cascade of three bioorthogonal reactions – an inverse electron-demand DielsAlder reaction, a retro-Diels-Alder reaction/cheletropic extrusion, and lactonization, three key
components are released (Fig 1.1). This design features a prodrug that is activated under near
physiological conditions (PBS buffer, pH 7, 37 C) wherein the rate of the inverse electron-demand
Diels-Alder reaction is expected to be greatly enhanced. Then the formed norbornenone
intermediate readily undergoes a cheletropic reaction to extrude CO whilst forming an aromatic
ring. Post-aromatization, the hydroxyl group is now poised to undergo an anticipated facile
lactonization to release the free drug. Release of both CO and free drug leaves the original scaffold
as a blue fluorescent compound that can be used to track release progress (Fig 1.1).
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Figure 1.1 A cascade prodrug system for delivery of CO another drug payload, and a fluorescent
by-product.

1.2

Results and Discussion
1.2.1

Design and synthesis of CO cascade prodrug for combination therapy

The preparation of the prodrug system (Fig 1.2) was designed such that any compatible
drug or agent bearing a free hydroxyl group or amino group can be easily conjugated. The latent
CO is caged in the scaffold containing the carboxylic acid portion from readily available starting
material, 2-hydroxyphenylacetic acid. The 1,3-dicarbonyl compound, compound 5, is constructed
using Meldrum’s acid. Then, acenapthenequinone is made to react with compound 5 in an Aldol
Condensation step followed by a deprotection to obtain compound 7. This setup a carboxylic acid
handle wherein a compatible payload can be easily conjugated via amidation or esterification.
Once the payload is appended and after phenol deprotection, the alkyne component is introduced
in the ortho-phenolic group by Mitsunobu reaction to complete the prodrug. The modularity of
this synthetic design offers possibility to synthesize prodrugs of CO that can release various drugs.
1.2.2

Confirmation of release of CO and payload drug

Initially, the feasibility of this prodrug system probed by using a simple model compound
10a. The CO and payload releasing capacity of a 10a was studied through fluorescence
spectroscopy, CO-myoglobin assay, and NMR studies. Because a fluorescent cyclized product is
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also produced as CO and the payload are released, the progress of cascade reaction of the prodrug
can be monitored by fluorometric studies. The fluorescent cyclized product is characterized by
excitation wavelength of 355 nm and emission wavelength of 460 nm (Fig 1.3a). Time-dependent
increase in fluorescence intensity was observed, indicating that CO and the payload are released
as the prodrug is incubated in aqueous solution at physiological pH, providing indirect
confirmation of CO release (Fig 1.3b). Correlation of the data using Sigmaplot revealed that the
half-life of the model prodrug is 0.66  0.05 h. To supply direct proof that indeed CO is being
released, a modified CO-myoglobin assay75 was conducted. Indeed, it was shown that incubation
of deoxymyoglobin with the prodrug produces CO-myoglobin as demonstrated by the change in
the absorbance spectrum that is characteristic of CO-bound myoglobin (Fig 1.3c).

9

Figure 1.2 Synthesis of cascade prodrug system that allows attachment of compatible second drug
payload.
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Figure 1.3 (a) Fluorescence spectrum of cyclized product, (b) Monitoring of fluorescence increase
indicating release of CO and payload, (c) CO-myoglobin assay for the direct detection
of CO release.
To gain preliminary insights into the possible mechanism of CO and payload release,
reaction progress of 10a was followed by 1H NMR experiments. A 10-mM solution of model
prodrug 10a in DMSO-d6: PBS in D2O was incubated at 37 C while taking NMR spectra at
indicated time points. The simplicity of the structure of prodrug 10a allowed for easy monitoring
of reaction progress. Scrutinizing the spectroscopic changes of four sets of protons from prodrug
10a - three CH2 peaks labelled b-d and the most deshielded aromatic proton labelled as a proved
to be informative (Fig 1.4). As expected, the peaks corresponding to the norbornenone
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Figure 1.4 NMR monitoring of prodrug 10a. (A) 10a in pure DMSO-d6. (B) Incubation in DMSOd6:PBS in D2O after 30 min, (C) 75 min, (D) 120 min, (E) 165 min. (F) Proposed
mechanism of release involves a three-reaction se-quence – inverse demand Diels Alder
reaction, retro-Diels Alder/cheletropic extrusion, and lactonization to release CO, benzyl
alcohol, and the fluorescent cyclized product.
intermediate were not observed, confirming that the CO extrusion step is very fast and the DielsAlder reaction step is rate-limiting for CO release as has been studied previously. Aside from the
peaks corresponding to the intact prodrug 10a, cyclized product 11 and benzyl alcohol, another set
of peaks possibly from the pre-lactonization intermediate Y was also present. As reaction
progressed, peaks from the intact prodrug and intermediate Y decreased while peaks corresponding
to the cyclized product 11 and benzyl alcohol steadily increased with a ratio of 1:1. After 24 h,
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both intact prodrug 10a and intermediate Y were no longer observable and only peaks
corresponding to the cyclized product 11 and benzyl alcohol were present.
Having confirmed the release of CO and model payload from model compound 10a, 10b
and 10c were prepared to deliver CO together with a real drug payload. Because CO has been
shown to exhibit synergistic effects with anticancer agents, the cytotoxic agent podophyllotoxin
was initially conjugated to the CO releasing scaffold. However, HPLC and NMR analysis showed
that prodrug 10c does not lead to clean release of podophyllotoxin and cyclized product 11 (Fig
1.5). After 90 minutes of incubation (Fig 1.5b), NMR analysis shows that aside from the cyclized
product and free podophyllotoxin being formed, another entity is being formed which is the end
product after longer incubation time. While it is clear that podophyllotoxin is being released
initially, the final product after incubation is not free podophyllotoxin (Fig 1.5d) making it difficult
to assess the utility of this prodrug system for proof-of-concept studies.

Figure 1.5 Podophyllotoxin as drug payload 10c. (A) 10c in DMSO-d6,(B) Incubation of 10c in
DMSO-d6:PBS in D2O after 90 min, (C) After 16 h, (D) Addition of free
podophyllotoxin to reaction mixture in (c).
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CO has been well-documented to exert anti-microbial effects either through directly
targeting bacterial survival machinery40,82 or through activating the killing potential of the host’s
phagosome in response to microbial invasion18,83. Co-administration of CO with known antibiotics
such as metronidazole, amoxicillin, and clarithromycin has been shown to enhance the efficacy of
these antibiotics against Helicobacter pylori, a causative agent in gastric ulcer.17 Hence, we
prepared prodrug 10b such that it would release three components – CO, an antibiotic payload
(metronidazole), and a fluorescent reporter molecule.
The formation of these three components following incubation of prodrug 10b in PBS
buffer was examined using RP-HPLC. For reference, a mixture containing 25 M each of the
prodrug 10b, free drug metronidazole, and cyclized product 11 were prepared (Fig 1.6). Then, a
25 M solution of prodrug 10b was incubated at 37 C, pH 7. At time 0 (Fig 1.6b), only the peak
for the prodrug was observable. After 30 min (Fig 1.6c), two new peaks corresponding to the
cyclized product and free metronidazole emerged while the intensity of the peak for the intact
prodrug decreased. As 10b was being consumed, the free drug and 11 were in turn produced (Fig
1.6c-f). After 6 h (Fig 1.6f), the peak for the intact prodrug was almost undetectable while the
peaks corresponding to the free drug and cyclized by-product appeared to level off to the same
peak area as that of the 25 M mixture shown in Fig 1.6a. Quantification of the release of the free
drug showed that at the 6-h time point, around 85% of the free drug had already been released (Fig
1.6g-f). It is also worth noting that the prodrug fell apart in PBS buffer, pH 7 at 37 C in a clean
manner without any other discernable artifacts aside from the three components.
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Figure 1.6 (A) Mixture of 25 𝜇M each of prodrug 10b, 11, and metronidazole. (B-F) HPLC
chromatogram after incubation of 25 𝜇M of 10b in PBS buffer, pH 7, 37 °C at time 0
h (B), 1 h (C), 2 h (D), 4 h (E), 6 h (F). (G) Release profile of 10b. (H) Quantification
of the accumulated free metronidazole released over time.

To verify CO release in biological systems, the formation of blue fluorescence of the
cyclized product 11 in cell imaging studies using RAW 264.7 cells was monitored. After
incubation of 10b for 6 h, we found that the cells exhibited a dose-dependent increase (qualitative)
in blue fluorescence formation (Fig 1.7 top panel) indicating that indeed CO was released from
prodrug 10b. To directly assay CO release in cell cultures, a CO-selective turn-on fluorescent
probe COP-184 was used. An increase in green fluorescence (qualitative) relative to the negative
control (Fig 1.7 bottom panel) was observed verifying that indeed CO was present inside the cell.
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Certainly, these results indicate that cyclized product 11 can be used as a fluorescent reporter
molecule to monitor CO and drug release from the prodrug.

Figure 1.7 Concentration-dependent increase in fluorescence intensity of 11 (blue channel) and
COP-1 probe (green channel) after 6 h incubation of prodrug 10b. All experiments
were conducted side by side. Top panel – 10b only, Bottom panel – 10b + COP-1.

1.2.3

Prodrug System in the Biological Milieu

To further demonstrate that this cascade prodrug concept can work in living systems, we
probed the ability of prodrug 10b to deliver metronidazole and CO in H pylori, and juxtaposed its
growth inhibitory activity against the antibiotic metronidazole. As expected, metronidazole
exhibited a dose-dependent growth inhibitory effect against H. pylori strain 26695 with a MIC90
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of 2.5 mg/mL. In contrast, it took only 0.31 g/mL of prodrug 10b to achieve greater than 90%
growth inhibition against H. pylori (Fig 1.8). This is an enhancement of over 8-fold in potency.
Further, with metronidazole’s molecular weight (171) being only less than 1/3 of that of 10b (MW:
562), the true enhancement in potency for 10b was over 26-fold in terms of molar concentrations.
As controls, prodrug 10a, which releases CO only without metronidazole, and cyclized product 11
exhibited no or minimal inhibition at the same concentration (0.31 g/mL). Such results are
consistent with the observed bacterial sensitization effect of CO toward existing antibiotics.
Collectively, these results demonstrated the feasibility of using prodrug 10b to co-deliver CO and
metronidazole in a biological milieu. These results also herald the potential of combinational
therapy of CO and other drugs such as metronidazole using a single prodrug.

Figure 1.8 Inhibition of H pylori growth in BHI-β-cyclodextrin medium following treatment of
metronidazole, 10b, 10a, and 11 in 1% DMSO. (*no visually detectable growth of H.
pylori)
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The viability of this prodrug to act as an antimicrobial agent depends on its opposite
toxicity profiles in microbes and in host cells. Therefore, the toxicity profiles of the prodrug (10)
and the cyclized product (11) were tested in a crystal violet assay of RAW264.7 macrophage cells.
No toxicity was observed at up to 100 M of both prodrugs 10a and 10b and fluorescent byproduct 11 after 24 h of incubation (Fig 1.9).

Figure 1.9 Cytotoxicity profiles of 10a, 10b, metronidazole and 11 in RAW 264.7.

1.3

Experimental Section
1.3.1

General Experimental Details

Unless otherwise noted, all reactions were carried out under nitrogen atmosphere using
glassware that was previously oven-dried overnight with magnetic stirring and, all reagents were
obtained from commercial suppliers (Sigma Aldrich, VWR International, and Oakwood
Chemicals) and used without further purification. Thin layer chromatography was performed on
glass-backed silica gel TLC plates (250 m) using mixtures of hexanes/ethyl acetate as eluent, and
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using either UV light, iodine powder, or potassium permanganate stain for visualization. Column
chromatography was done using Silica Flash P60 silica gel (230-400 mesh). 1H and 13C NMR
spectra were recorded on Bruker-400 spectrometers (400 MHz and 100 MHz, respectively).
Chemical shifts were reported in ppm relative to residual solvent peaks (7.26 for 1H, 77.1 for
13C, CHCl3/CDCl3) and ( 2.49 for 1H, and 39.1 for 13C, DMSO/DMSO-d6). Data are reported
as follows: bs= broad singlet, s= singlet, d= doublet, t= triplet, q= quartet, m= multiplet, dd=
doublet of doublets, ddd= doublet of doublet of doublets, ddt= doublet of doublets of triplets, td=
triplet of doublets; coupling constants in Hz; integration. Accurate mass measurements were
acquired at the Mass Spectrometry Facilities at Georgia State University. For spectrophotometric
studies, Shimadzu PharmaSpec UV-1700 was used as UV-Vis spectrophotometer; while
Shimadzu RF-5301PC fluorimeter was used for fluorescent studies.
1.3.2

Synthesis of CO-drug conjugates

Compound 1: To a solution of prop-2-yn-1-ol (0.52 mL, 8.92 mmol) and imidazole (2.3 g, 26.8
mmol) in dry DMF (1.5 mL) cooled over an ice-bath, tert-butyldiphenylsilyl chloride (2.70 g, 9.81
mmol) was slowly added. Then, the reaction mixture was warmed to room temperature, and stirred
for 1 h. Ethyl acetate was added followed by washing with saturated ammonium chloride solution
(3  15 mL). The aqueous solution was extracted using ethyl acetate (2  25 mL). The combined
organic layer was washed with water and brine, dried over Na2SO4, and concentrated in vacuo to
give a yellow oil. The crude product was purified by silica gel column chromatography with an
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eluent consisting of hexanes only to give white solid (2.52 g, 96%). 1H NMR (CDCl3): δ = 7.797.76 (m, 4H), 7.51-7.42 (m, 6H), 4.37 (d, J = 2.4 Hz, 2H), 2.40 (t, J = 2.4 Hz, 1H), 1.13 (s, 9H).
C NMR (CDCl3): δ =135.7, 133.1, 130.0, 127.9, 82.1, 73.2, 52.6, 26.8, 19.3. HRMS (ESI)
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calculated for C19H23OSi [M+H]+: m/z 295.1518, found 295.1511.
Compound 2: To a solution of compound 1 (1.32 g, 4.47 mmol) in dry THF was added dropwise
n-butyllithium solution in THF (2.68 mL, 6.71 mmol, 2.5 M) at -78 °C under N2. After stirring for
1 h, paraformaldehyde (403 mg, 13.41 mmol) was added with stirring at -78 °C. After 30 min, the
reaction mixture was allowed to stir at room temperature for 3 h. After reaction completion,
saturated ammonium chloride solution was added followed by extraction with ethyl acetate (3 
30 mL). The combined organic layer was washed with brine, dried over sodium sulfate, and
concentrated under reduced pressure to yield a colorless oil. The crude product was purified by
silica gel column chromatography with an eluent consisting of hexanes:ethyl acetate 100:30 to
give clear and colorless oil (1.12 g, 77%). 1H NMR (CDCl3): δ = 7.76-7.74 (m, 4H), 7.48-7.40 (m,
6H), 4.40-4.39 (m, 2H), 4.22-4.21 (m, 2H), 1.88 (bs, 1H), 1.10 (s, 9H). 13C NMR (CDCl3): δ =
135.7, 133.1, 129.9, 127.8, 84.1, 83.6, 52.7, 51.1, 26.8, 19.2. HRMS (ESI) calculated for
C20H24O2Si [M+H]+: m/z 323.1462, found 323.1454.

20
Compound 3: To a solution of phenylacetic acid (3.0 g, 19.7 mmol) in dry DMF (6 mL) cooled
over an ice-bath, imidazole (4 g, 58.8 mmol) and tert-butyldiphenylsilyl chloride (11.4 g, 41.5
mmol) were slowly added. After addition was complete, the reaction mixture was warmed to room
temperature, and stirred for 12 h. Diethyl ether was added followed by washing with saturated
ammonium chloride solution. The aqueous solution was extracted using diethyl ether (3 x 25 mL).
The combined organic layer was washed with water and brine, dried over Na2SO4, filtered, and
concentrated in vacuo to give yellowish solids. The crude product was dissolved in THF followed
by addition of K2CO3 (5.45 g, 39.4 mmol). A small amount of water was added to dissolve K2CO3.
Then methanol was added to make a homogenous solution. After overnight stirring, THF and
methanol were removed by rotary evaporation to give a cloudy residue. Water was added and the
organic layer was separated. The aqueous layer was extracted using ethyl acetate (3  30 mL). The
organic layer was saved while the aqueous layer was acidified and extracted with ethyl acetate (3
 15 mL). The two organic layers were combined, washed with water and then brine, dried over
Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column
chromatography with an eluent consisting of hexanes and ethyl acetate in a 100:15 ratio to give
creamy white solid (4.14 g, 54%). 1H NMR (CDCl3): δ = 7.77-7.75 (m, 4H), 7.46-7.37 (m, 6H),
7.24-7.22 (m, 1H), 6.87-6.85 (m, 2H), 6.44-6.43 (m, 1H), 3.89 (s, 2H), 1.09 (s, 9H).
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C NMR

(CDCl3): δ = 178.4, 153.8, 135.5, 132.4, 131.1, 130.1, 128.4, 128.0, 124.1, 121.1, 119.0, 36.4,
26.4, 19.4. HRMS (ESI) calculated for C24H26O3SiNa [M+Na]+: m/z 413.1549, found 413.1546.
Compound 4: To a solution of compound 3 (2.0 g, 5.1 mmol), meldrum’s acid (1.1 g, 7.68 mmol),
and dimethylaminopyridine (1.6 g, 7.68 mmol) in dichloromethane was added 1-ethyl-3-(3dimethylaminopropyl)carbodiimide in small portions while the reaction was being stirred at 0 °C.
After stirring for 2 h, the reaction mixture was diluted with 0.5 N HCl (50 mL) and then extracted

21
with dichloromethane (3  30 mL). The organic layer was washed with water (2  25 mL), dried
over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel column
chromatography with an eluent consisting of hexanes and ethyl acetate in a 100:2 ratio to give
yellow oil (1.40 g, 53%). 1H NMR (CDCl3): δ = 15.77 (s, 1H), 7.76-7.74 (m, 4H), 7.45-7.38 (m,
6H), 7.21 (d, J = 4.4 Hz, 1H), 6.87 (t, J = 4.0 Hz, 2H), 6.46 (d, J = 9.2 Hz, 1H), 4.72 (s, 2H), 1.79
(s, 6H), 1.10 (s, 9H). 13C NMR (CDCl3): δ = 196.5, 170.9, 160.5, 153.8, 135.4, 132.1, 131.1, 130.1,
128.5, 128.0, 123.8, 121.1, 118.9, 105.1, 91.2, 38.0, 27.0, 26.4, 19.4. HRMS (ESI) calculated for
C30H32O6SiNa [M+Na]+: m/z 539.1866, found 539.1851.

Compound 5: To a solution of compound 4 (3.00 g, 5.8 mmol) in toluene (15 mL) was added
isopropyl alcohol (547 mg, 11.61 mmol). The reaction mixture was allowed to stir for 30 min
under reflux at 110 °C. Toluene was removed by rotary evaporation and the colorless oily crude
product (a mixture of keto-enol tautomers) was used without purification in the next step. 1H NMR
(CDCl3): δ = 12.59 (s, 0.15H), 7.84-7.82 (m, 4.19H), 7.49-7.41 (m, 6.28H), 7.25-7.22 (m, 1.11H),
6.91-6.84 (m, 2.09H), 6.56-6.51 (m, 1.05H), 4.91 (s, 0.156), 4.07 (s, 1.71H), 3.81 (s, 0.325H),
3.56-3.54 (m, 1.71H), 1.57-1.54 (m, 9H), 1.18-1.17 (m, 9.33H).
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C NMR (CDCl3): δ = 200.7,

177.0, 172.7, 170.8, 166.4, 153.6, 153.5, 135.3, 132.3, 132.1, 131.4, 131.2, 130.0, 129.9, 128.2,
127.9, 127.8, 125.4, 124.2, 121.2, 120.9, 119.0, 118.9, 90.9, 81.5, 80.5, 60.2, 49.6, 45.4, 36.2, 28.3,
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27.9, 26.4, 26.2, 20.9, 19.3, 14.1. HRMS (ESI) calculated for C30H36O4SiNa [M+Na]+: m/z
511.2281, found 511.2297.
Compound 6: To a solution of compound 5 (2.3 g, 4.66 mmol) in THF (30 mL) was added
acenaphthylene-1,2-dione (934 mg, 5.13 mmol). Then methanol (10 mL) was added followed by
triethylamine (711 mg, 6.99 mmol). After 24 h, the reaction mixture was dried in the rotary
evaporator. The residue was dissolved in acetic anhydride (20 mL), allowed to stir in an ice-bath;
and then four drops of sulfuric acid was added. After stirring for 5 min, methanol and diethyl ether
was added while stirring over an ice-bath. Then the mixture was filtered via suction filtration. The
purple filtrate was concentrated in vacuo and then the residue was dissolved in ethyl acetate,
washed with water, saturated NaHCO3, and brine, dried over Na2SO4, and concentrated in vacuo
to give purple solid, which was used without further purification (2.0 g, 67%). 1H NMR (CDCl3):
δ = 8.74 (d, J = 7.2 Hz, 1H), 8.01-7.99 (m, 1H), 7.84-7.82 (m, 1H), 7.77-7.73 (m, 1H), 7.67-7.55
(m, 5H), 7.54-7.50 (m, 1H), 7.43-7.27 (m, 5H), 7.19-7.16 (m, 2H), 7.03-6.98 (m, 2H), 6.68-6.66
(m, 1H), 1.69 (s, 9H), 0.77 (s, 9H).
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C NMR (CDCl3): δ = 197.0, 168.1, 162.3, 154.4, 145.3,

135.8, 135.5, 132.5, 131.6, 131.5, 130.8, 130.3, 129.7, 128.9, 128.5, 127.9, 127.7, 127.3, 122.9,
122.4, 121.3, 120.3, 81.6, 28.6, 26.6, 19.4. HRMS (ESI) calculated for C42H39O4Si [M+H]+: m/z
635.2618, found 635.2622.
Compound 7: To a solution of compound 6 (1.50 g, 2.36 mmol) in dichloromethane (24 mL) was
added trifluoroacetic acid (12 mL) while the reaction was being stirred at 0°C. The reaction
mixture was allowed to stir for 1.5 h and then concentrated in vacuo to give a green residue. The
crude product was purified by silica gel column chromatography with an eluent consisting of
dichloromethane only to give green solid (1.17 g, 85%). 1H NMR (CDCl3): δ = 10.44 (bs, 1H),
8.84 (d, J = 7.2 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.83-7.79 (m, 1H), 7.68
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(d, J = 6.8 Hz, 1H), 7.63-7.59-7.54 (m, 5H), 7.43-7.40 (m, 2H), 7.31 (bs, 3H), 7.18 (bs, 2H), 7.117.07 (m, 1H), 7.04-7.00 (m, 1H), 6.76-6.74 (m, 1H), 0.82 (s, 9H). 13C NMR (CDCl3): δ = 203.2,
171.2, 161.5, 155.0, 154.4, 146.7, 135.6, 132.1, 131.6, 131.0, 130.6, 130.4, 130.1, 129.7, 129.6,
129.5, 128.7, 128.2, 127.9, 123.4, 123.0, 121.6, 121.3, 120.7, 107.7, 26.6,19.5. HRMS (ESI)
calculated for C38H30O4SiNa [M+Na]+: m/z 601.1811, found 601.1833.

General procedure for synthesis of compound 8: To a solution of compound 7 (1 eq), drug (1.5
eq), and N,N-dimethylaminopyridine (0.3 eq) in dry dichloromethane (10 mL), was added 1-ethyl3-(3-dimethylaminopropyl)carbodiimide (1.3 eq) while the mixture was being stirred at room
temperature. For work-up, the reaction mixture was diluted with ethyl acetate, washed with 10%
HCl and brine, dried over Na2SO4, and concentrated in vacuo to give 8a and 8b.
Compound 8a: Purple solid (382 mg, 85%). 1H NMR (CDCl3): δ = 8.65 (d, J = 7.2 Hz, 1H), 8.01
(d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.70-7.63 (m, 8H), 7.56-7.52 (m, 1H), 7.49-7.41 (m,
3H), 7.39-7.31 (m, 5H), 7.24-7.20 (m, 2H), 7.08-7.04 (m, 2H), 6.77-6.74 (m, 1H), 5.58-5.49 (m,
2H), 0.80 (s, 9H). 13C NMR (CDCl3): δ = 196.7, 169.7, 162.5, 154.4, 152.8, 145.3, 136.3, 135.7,
135.4, 133.0, 132.3, 131.4, 130.8, 130.3, 129.9, 128.9, 128.7, 128.5, 128.3, 128.2, 128.2, 127.8,
127.7, 127.4, 123.0, 122.6, 122.2, 121.3, 120.3, 110.4, 66.2, 26.5, 19.3. HRMS (ESI) calculated
for C45H37O4Si [M+H]+: m/z 669.2461, found 669.2478.
Compound 8b: Purple solid (108 mg, 85%). 1H NMR (CDCl3): δ = 8.60 (d, J = 7.2 Hz, 1H), 8.03798 (m, 2H), 7.83 (d, J = 8.4 Hz, 1H), 7.723 (t, J = 8.0 Hz, 1H), 7.65-7.61 (m, 3H), 7.57-7.496 (m,
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3H), 7.40-7.36 (m, 2H), 7.32-7.26 (m, 3H), 7.19-7.15 (m, 2H), 7.04-6.98 (m, 2H), 6.68 (d, J = 7.6
Hz, 1H), 4.79-4.68 (m, 4H), 2.62 (s, 3H), 0.75 (s, 9H). 13C NMR (DMSO-d6): δ = 196.3, 171.8,
162.4, 154.4, 152.7, 152.1, 145.4, 138.5, 135.7, 135.4, 133.6, 132.8, 132.4, 131.5, 131.4, 130.1,
129.99, 129.85, 129.1, 128.6, 127.9, 127.7, 127.6, 123.1, 122.9, 122.93, 121.98, 121.4, 120.3,
109.5, 63.0, 45.6, 26.5, 19.40, 14.6. HRMS (ESI) calculated for C44H37N3O6SiNa [M+Na]+: m/z
754.2349, found 754.2329.
General procedure for the synthesis of compound 9. To a solution of compound 8 (1 eq) in dry
THF protected with a nitrogen balloon was added tert-butylammonium fluoride (1.05 eq, 1.0 M in
THF) with stirring at room temperature. After a few minutes, reaction mixture was diluted with
ethyl acetate, washed with water and brine, dried over Na2SO4, and concentrated in vacuo. The
crude product was washed with a small amount of cold methanol and then filtered to give 9a and
9b.
Compound 9a: Green solid (93 mg, 72%). 1H NMR (DMSO-d6): δ = 10.02 (s, 1H), 8.46 (d, J =
7.2 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.73-7.68 (m, 2H), 7.55-7.41 (m,
3H), 7.39-7.30 (m, 5H), 7.04 (d, J = 8.0 Hz, 1H), 6.94 (t, J = 7.6 Hz, 1H), 5.41 (s, 2H). 13C NMR
(DMSO-d6): δ = 196.6, 169.4, 161.4, 156.4, 150.9, 144.3, 136.3, 131.6, 131.5, 131.0, 130.4, 130.2,
129.2, 128.9, 128.5, 128.1, 127.8, 127.3, 124.0, 120.9, 118.8, 117.1, 115.9, 109.1, 65.5. HRMS
(ESI) calculated for C29H18O4 [M+H]+: m/z 431.1283, found 431.1278.
Compound 9b: Green solid (183 mg, 87%). 1H NMR (DMSO-d6): δ = 10.07 (s, 1H), 8.46 (d, J =
7.2 Hz, 1H), 8.24 (d, J = 8.4 Hz, 1H), 8.05-8.03 (m, 2H), 7.82-7.78 (m, 1H), 7.75-7.71 (m, 1H),
7.52 (d, J = 7.2 Hz, 1H), 7.35-7.30 (m, 2H), 7.05 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 7.6 Hz, 1H), 4.72
(s, 4H), 2.51 (s, 3H). 13C NMR (DMSO-d6): δ = 196.3, 170.4, 161.4, 156.4, 151.9, 150.7, 144.3,
138.6, 133.2, 131.7, 131.6, 131.0, 130.4, 130.2, 129.1, 129.0, 127.9, 127.4, 124.1, 120.8, 118.8,
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117.1, 116.0, 108.8, 62.3, 45.1. HRMS (ESI) calculated for C28H20N3O6 [M+H]+: m/z 494.1352,
found 494.1337.

General procedure for the synthesis of compound 10: To a solution of compound 9 (1 eq),
compound 2 (1.5 eq), and triphenylphosphine (1.5 eq) dissolved in dry DMF:THF 3:10 was added
diisopropylazodicarboxylate (1.5 eq) dropwise with stirring at room temperature. After 15 min,
the reaction mixture was concentrated in vacuo and then dissolved in dichloromethane, washed
with water and brine, dried over Na2SO4, and concentrated in vacuo at below 20 °C. The residue
was loaded into a short column and then eluted using dichloromethane only first and then
CH2Cl2:EtOAc 100:30. The violet fractions were combined and then concentrated in vacuo to give
purple solids. These solids were dissolved in THF (3 mL) and then tert-butylammonium fluoride
(1.1 eq, 1.0 M in THF) was added while the mixture was stirred at room temperature. After 20
min, the reaction mixture was concentrated in vacuo and directly loaded into a silica gel column
using CH2Cl2:EtOAc 100:50 as eluent.
Compound 10a: Dark purple solid (35 mg, 32%).1H NMR (DMSO-d6): δ = 8.49 (d, J = 7.2 Hz,
1H), 8.20 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.75-7.70 (m, 2H), 7.56-7.48 (m, 4H), 7.457.35 (m, 4H), 7.27 (d, J = 8.4 Hz, 1H), 7.13 (t, J = 7.6 Hz, 1H), 5.41 (s, 2H), 5.23 (t, J = 6.0 Hz,
1H), 4.86 (s, 2H), 4.05 (d, J = 6.0 Hz, 2H), 4.87 (s, 2H), 4.72 (s, 4H), 4.07 (s, 2H).

13

C NMR

(DMSO-d6): δ = 169.2, 161.3, 155.8, 151.7, 144.4, 136.2, 131.9, 131.6, 131.1, 130.4, 129.8, 129.1,

26
128.9, 128.6, 128.1, 127.8, 127.7, 124.1, 120.7, 119.0, 112.8, 109.2, 87.6, 78.9, 65.6, 55.8, 48.9.
HRMS (ESI) calculated for C33H23O5 [M+H]+: m/z 499.1545, found 499.1561.
Compound 10b: Dark purple solid (35 mg, 32%). 1H NMR (DMSO-d6): δ = 8.44 (d, J = 7.2 Hz,
1H), 8.23 (d, J = 8.0 Hz, 1H), 8.06-8.04 (m, 2H), 7.81-7.78 (m, 1H), 7.74-7.70 (m, 1H), 7.56 (d, J
= 6.8 Hz, 1H), 7.54-7.49 (m, 1H), 7.39 (dd, J = 7.6, 1.6 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.167.12 (m, 1H), 5.26 (s, 1H), 4.87 (s, 2H), 4.72 (s, 4H), 4.07 (s, 2H), 2.51 (s, 3H). 13C NMR (DMSOd6): δ = 195.9, 170.2, 161.3, 155.8, 151.9, 151.6, 144.4, 138.6, 133.2, 131.9, 131.8, 131.1, 130.5,
130.0, 129.2, 129.1, 129.0, 127.9, 127.7, 124.1, 120.8, 120.0, 118.9, 112.8, 108.9, 87.6, 78.9, 62.4,
55.8, 48.9, 45.1, 14.0. HRMS (ESI) calculated for C32H24N3O7 [M+H]+: m/z 562.1614, found
562.1581.
1.3.3

Characterization of cyclized product 11 from prodrugs 10a and 10b

Compound 11: Compounds 10a or 10b (10 mg) were dissolved in DMSO and then diluted with
PBS. The solution was incubated at 37 °C. After 24 h, the purple color of the solution disappeared
and the reaction mixture exhibited blue fluorescence under 365 nm of light. Water was added to
precipitate the cyclized product fully followed by ethyl acetate extraction. The organic layer was
washed with water, dried over sodium sulfate, and concentrated under reduced pressure to give a
yellow solid. The crude solid was purified via column chromatography using hexane:EtOAc as
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eluent to give yellow solids. 1H NMR (CDCl3): δ = 9.25 (d, J = 7.2 Hz, 1H), 8.46 (d, J = 7.2 Hz,
1H), 8.42 (d, J = 7.6 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.80-7.76 (m,
1H), 7.60-7.56 (m, 1H), 7.47-7.43 (m, 1H), 7.23-7.21 (m, 2H), 5.42 (s, 2H), 5.04 (s, 2H). 13C NMR
(CDCl3): δ = 157.0, 140.7, 139.6,135.9, 135.2, 133.7, 132.6, 131.3, 130.0, 129.1, 128.7, 128.7,
128.4, 128.3, 127.4, 124.3, 123.3, 122.1, 119.6, 118.4, 68.9, 65.9. HRMS (ESI) calculated for
C25H15O3 [M+H]+: m/z 363.1021, found 363.1013.
1.3.4

CO-release kinetics: spectrofluorometric studies

Because the by-product after CO release is fluorescent, the release kinetics of the CO-drug
conjugate can be conveniently studied by monitoring the fluorescence intensity of the solution.
The kinetic studies were performed using slit width of 3 nm. First, the emission and excitation
spectra and wavelength of cyclized product 11 were obtained (Figure S1a). Using 355 nm and 460
nm as excitation and emission wavelengths, respectively, the CO release rate of model prodrug
10a (25 µM, 4:1 DMSO:PBS) was measured. Data points were collected every 15 min for the
first hour to every 30 min in the succeeding hours. To determine the first order reaction rate
constant, the fluorescence intensity was plotted against time and the obtained curve was processed
using Sigmaplot using the exponential growth to maximum function with 3 parameters.
1.3.5

Detection of CO release: the CO-myoglobin assay

Direct detection of carbon monoxide release was done through a “two-compartment” Mb-CO
assay developed earlier.75 The set-up was assembled by putting a small vial inside a bigger vial
and sealing the system. The bigger vial contains the deoxy-Mb solution while the small vial
contains the CO-drug conjugate in DMSO/PBS. The deoxy-Mb solution was prepared by
degassing a solution of myoglobin in PBS (1 mg/mL, pH = 7.4) with nitrogen for at least 20 min,
and then converted to deoxy-Mb by adding freshly prepared solution of sodium dithionite (22
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mg/mL). Then a solution of CO-drug conjugate in DMSO was added to the inner vial containing
PBS via a syringe. The whole set-up was then incubated at 37  C. At the end of 6 h, the set-up
was cooled in an ice-bath for 10 min to increase the solubility of CO gas in water, after which, the
incubated solution was immediately transferred into a cuvette for UV-Vis spectral measurements.
1.3.6

Initial studies on the mechanism of release: NMR studies

As initial mechanistic studies, the release of a model prodrug from 10a was studied using NMR.
At time 0, only DMSO was used as solvent to prevent cyclization. Then deuterated PBS was added
to make a final concentration of approximately 10 mM. The prodrug solution was incubated at 37
°C for 24 h. At indicated time points, the proton NMR spectrum of the solution was taken. After
24 h, most of the cyclized product precipitated out so more DMSO was added for a well-resolved
NMR spectrum. Shown below are the full NMR spectra of the prodrug 10a solution taken at
different time points.
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Figure 1.10 Full NMR spectrum of changes to 10b across different time points.
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1.3.7

Verification of the release of the three components (CO, drug, and 11): RPHPLC

Samples injected:
•

mixture containing 25 M each of prodrug 10b, metronidazole, and cyclized product 11

•

incubated solution of prodrug 10b (25 M) dissolved in 4:1 DMSO:PBS at 37 °C at
different time points

•

different concentration of the drug metronidazole (0, 5, 10, 15, 20, 25, and 30 M) for the
calibration curve

A 200 L aliquot of incubated sample was placed inside a 0.5 mL vial followed by dilution with
200 L of acetonitrile. The study was performed using the Shimadzu Prominence UFLC with a
reversed-phase analytical column (Waters C18 3.5 M, 4.6 x 100 mm) at 25 °C. The flow rate was
set at 0.5 mL/min. Gradient elution using acetonitrile and deionized water was used to elute out
the components of the sample. Elution conditions: 0-6 min 5% acetonitrile, 6-12 min 70%
acetonitrile, 12-30 min 70% acetonitrile; injection volume of 20 µL; detection wavelength of 254
and 280 nm. Experiments were done in triplicates.
1.3.8

Verification of CO release: fluorescent imaging in cell culture using either the
fluorescent by-product or the probe COP-1

Raw 264.7 cells were seeded on coverslips in 6-well plates one day before the experiment. The
CO-drug conjugate dissolved in DMSO was added to the cell culture media to give a final
concentration of 20 M or 40 M with 1% DMSO. In two other wells, the same was done with
the addition of COP-1 probe with a final concentration of 1 M. The cells were incubated with
CO-drug conjugate for 6 hours at 37 °C. Then, the cells were washed with PBS twice and fixed
with 4% paraformaldehyde for 30 minutes at room temperature. The cells were then washed with
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PBS again twice and the coverslips with cells were immersed in DI water. The coverslips were
mounted onto glass slides using the mounting media without DAPI (ProLong® Live Antifade
Reagent; P36974). The fluorescent imaging was performed on a Zeiss fluorescent microscope,
using DAPI imaging channel (excitation: 358 nm, emission: 461 nm) and FITC channel
(excitation: 490 nm, emission: 525 nm) for the fluorescence of COP-1. The concentrationdependent images were taken using the oil objective (40x). Experiments for compound 11 and
COP-1 probe were done side-by-side.
1.3.9

Cytotoxicity of CO-drug conjugates and cyclized product

For the crystal violet assay and cell-imaging studies, RAW 264.7 (ATCC® TIB-71™) within 10
passages was used. The cells were cultured in DMEM (Dulbecco’s Modified Eagle’s Medium)
supplemented with 10% fetal bovine serum (MidSci; S01520HI) and 1% penicillin-streptomycin
(Sigma-Aldrich; P4333) at 37 °C with 5% CO2. Fresh medium was replenished every other day.
The cells were treated with the compounds (0–100 μm) using 1% DMSO in DMEM for 24 h.
1.3.10 Growth Inhibition Assay Against Helicobacter pylori
Brain Heart Infusion(BHI)-ß-cyclodextrin was prepared by mixing 9.25 g BHI and 1 g ßcyclodextrin in 240 mL deionized water. Ten milliliter aliquots in 165-mL bottles were autoclaved
for 20 min and let cool at room temperature. Each bottle was charged with N2 for 10 min, then
with anaerobic mix (10% H2, 5% CO2, 85% N2), and then added 7.5 mL of O2 (5%). H pylori cells
from blood agar plates (24 h grown) were harvested and resuspended in BHI- ß-cyclodextrin with
an estimated OD600 for inoculum. Then 0.1 mL of the compounds (metronidazole, 10a, 10b, and
11) were added to each bottle to achieve final concentration of (2.5, 1.25, 0.63, 0.31, and 0.16
µg/mL) in 1% DMSO. The bottles were shaken well to homogenize then H pylori was inoculated
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with OD600 of around 0.04. The OD600 after incubation for 24 h at 37 °C, 200 rpm shaking was
recorded. Experiments were done in triplicates.

1.4

Conclusion
In summary, we have developed a modular platform that features a cascade reaction

sequence that is set in motion once the prodrug is placed in an aqueous environment leading to the
release of CO, a compatible drug payload, and a fluorescent reporter molecule. The release of both
CO and drug payload was monitored by the increase in characteristic blue fluorescence of the
reporter by-product. Further verification through NMR studies, RP-HPLC kinetic studies, cell
imaging, and antibacterial assay provide unambiguous evidence in support of the feasibility of the
cascade prodrug design.
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2.1

ORGANIC CO PRODRUGS WITH BENIGN BY-PRODUCTS

Introduction
2.1.1

Physiological and Therapeutic Potential of CO

The dual nature of carbon monoxide (CO) as a toxicant and a potential therapeutic is now
becoming increasingly recognized – it is not just a toxic gas but a potential medicine! Despite the
stigma linked to CO as a silent killer gas at high concentration, CO is constantly generated in the
human body from the catabolism of heme through the action of a family of heme oxygenases (HO),
the inducible HO-1 and the constitutively expressed HO-2 producing 0.07 mL CO/hr.85 The
metabolic drive for the endogenous production of CO is becoming clear as its physiological roles
are being uncovered, abolishing the obsolete view that CO is merely a waste by-product. At low
physiologically relevant levels, CO induces vasodilation86,87 and inhibits platelet aggregation12 by
activating soluble guanylyl cyclase (sGC) leading to the formation of cyclic GMP (cGMP). Other
fundamental physiological roles of CO were discovered such as in inflammation,88 mitochondrial
biogenesis,89 and autophagy90 among many other biological processes. Therefore it was not
surprising to find that CO administration in different disease models such as acute lung injury,91
acetaminophen-induced liver damage,92 experimental colitis,75 sepsis,93 organ transplantation,94,95
and many others further validated the therapeutic potential of CO. Due to convincing preclinical
studies, there have been intensive interests in studying CO-based therapeutics in human clinical
trials.
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2.1.2

Caging CO in carbonyl compounds

Caging carbon monoxide as carbonyl moieties in organic compounds is one strategy for
the delivery of CO for therapeutic purposes. Our group and others have demonstrated the
feasibility and advantages of using organic small molecules as carriers for CO (Fig2.1).6669,72,76,92,96-99

Most previously reported organic scaffold cage CO as a carbonyl group utilizing

various triggers such as exposure to aqueous environment, light activation, pH change, presence
of ROS, and presence of enzymes. These donors each have their own advantages and
disadvantages with regards to their utility as viable form of CO for therapeutic application. With
our lab’s long-standing interest in developing “CO in a pill” for eventual clinical applications, we
are continually searching for new chemistry/class of compounds capable of undergoing
decarbonylation to supply for therapeutic application.
Organic CO Prodrugs
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Herein, a new class of CO prodrugs based on 1,2-dicarbonyl compounds that was
specifically designed to utilize benign carriers with well-established safety profiles is presented.
Oxalyl chloride, one of the simplest 1,2-dicarbonyl compounds in the form of oxalates, is known
to decompose in water to produce CO, HCl, and CO2 (Fig 2.2a).100 Because of the reliability of
this chemistry, oxalyl chloride has been used as a convenient CO gas donor in carbonylation
reactions.101,102 Despite its usefulness in the laboratory setting, oxalyl chloride’s short half-life,
and production of stoichiometric amounts of HCl pose significant challenges to its utility in
biological and therapeutic applications. With CO fixed in the 1,2-dicarbonyl moieties, our goal
was to design a new class of CO donor involving benign carriers (Fig 2.2b).

Figure 2.2 (A) Decomposition of oxalyl chloride to produce CO, (B) Design of a CO donor
based on oxalyl chloride chemistry.
2.2

Results and Discussion
2.2.1

Survey of 1,2-dicarbonyl-based CO compounds

Because of enhanced electrophilicity arising from vicinal keto groups, 1,2-dicarbonyl
compound with appropriate leaving groups are susceptible to hydrolysis expelling one leaving
group and generating a ketoacid intermediate (Fig 2.3). CO is generated once this ketoacid
intermediate undergoes a subsequent decarboxylation and decarbonylation reactions. For oxalyl
chloride, this path predominates and thus form only CO, CO2, and HCl when placed in water.
However, when chloride leaving groups are replaced with other leaving groups, another
decomposition path may compete with the CO generating path.103,104 The ketoacid intermediate
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can undergo hydrolysis to expel the second leaving group and form oxalic acid without CO
generation. Therefore, the identity of the leaving group must be carefully selected to tune the
reaction in favor of the CO generating path.

Figure 2.3 Competing paths by which oxalyl-based CO prodrugs can breakdown in aqueous
solution – (a) CO-generating path; (b) oxalic acid as end product.

COP-1,84 a CO probe based on Pd-mediated carbonylation was used to quickly evaluate
the ability of oxalates with various attached leaving groups to release CO under aqueous solution
at room temperature. Chloride was replaced with various leaving groups having different pKa
values to survey the effect of pKa on CO release (Table 2.1). A 6-fold increase in fluorescence
turn-on intensity was observed with leaving groups having pKa of about 4. While increasing the
pKa of the leaving group to greater than 4 leads to compounds incapable of CO release, except in
a modest 0.1-fold increase with imidazole. According to previous reports, hydrolysis of
symmetrical oxalates occurs in two steps with the first step being at least two orders of magnitude
faster than the second hydrolysis.103 In certain cases and as is shown in the later section, the
ketoacid with good leaving groups is stable enough to be isolated. The nature of the attached
leaving group to the keto acid influence the decomposition pathway it goes through (Fig 2.3). It
appears that leaving groups with pKa less than 4 facilitate to a certain extent the CO releasing
pathway.
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Table 2.1 Effect of pKa on CO-releasing capability of 1,2-dicarbonyl compounds
Compounds
pKa
COP-1 turn on?

4.09

Yes, 6-fold

6.23

No

8.3

No

10

No

14.5

Yes, 0.1 fold

Based on the results above, different leaving groups that fall within the 1-4 pKa range were
considered. In 1989, 2,2’-oxalyldisaccharin was used as a coupling reagent for the synthesis of
amides, esters, and thioesters from potassium carboxylates at 45 °C using DMF as solvent.105 The
activation of potassium carboxylate salts by 2,2’-oxalyldisaccharin involve the release of carbon
dioxide and carbon monoxide (Fig 2.4). Even though CO release was observed in DMF and an
activating carboxylic acid was necessitated, this reaction became an inspiration to explore the
utility of the oxalate moiety as caged CO with leaving groups such as saccharin.
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Figure 2.4 An interesting oxalyl-based compound that releases CO.

2.2.2

CO yield of saccharin and acesulfame prodrugs

Saccharin and acesulfame, two common non-calorific sweeteners, have pKas that fall
within the range, 1.6 and 3.0, respectively. Therefore, CO prodrugs BW-CO-306 and BW-CO307 were made in one step from the reaction between commercially available sweeteners saccharin
and acesulfame, respectively, with oxalyl chloride in the presence of triethylamine (Fig 2.5). BWCO-308, a saccharin derivative, was prepared to study the effect of modification of the saccharin.

Figure 2.5 Preparation of potential CO prodrugs

Initially, the CO releasing capacity of prodrug BW-CO-306 was qualitatively determined
using a household CO detector, COP-1 probe, and CO-myoglobin assay. Gratifyingly, both
qualitative determinations gave positive results with BW-CO-306. The CO release yield were then
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quantified using an Agilent 7820A GC with TCD as detector. CO prodrugs BW-CO-306 and BWCO-307 released, 76% ± 6 and 92% ± 3 CO, respectively when dissolved in 4 to 1
acetonitrile:water and incubated at 37 °C for 1 h (Fig 2.6). On the other hand, no CO was detected
from prodrug BW-CO-308.
%CO

%CO2

120

% CO YIELD

100
80
60
40
20
0
BW-CO-306

BW-CO-307

BW-CO-308

compound 4 intermediate 5

Figure 2.6 GC-TCD analysis of CO and CO2 yield of potential CO prodrug in acetonitrile:water
4:1 at 37 °C, incubation time = 1 h

An LC-MS method was used to analyze the proportion of prodrug BW-CO-306 that is
converted to oxalic acid. Using this method, 47 µM of oxalic acid was produced from a 200-µM
sample of prodrug BW-CO-306. Therefore, CO production is estimated to be about 75%, which
agrees well with the results generated from the GC-TCD experiments.
2.2.3

Initial Studies on Mechanism of Release

As proof that the designed prodrug needs to undergo hydrolysis first to unmask the ketoacid
intermediate which is the source of CO, intermediate 5, was synthesized from compound 4 (Fig
2.6). Compound 4, an unsymmetrical oxalyl derivative bearing saccharin and tert-butanol as
leaving groups, is expected to undergo hydrolysis readily to expel saccharin and exist as mono
tert-butyl oxalate which is not expected to release CO. Compound 5, on the other hand, is expected
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to undergo decarboxylation followed by decarbonylation. In agreement to this, no CO nor CO2
were detected from compound 4 while around 40% CO and CO2 were generated from the ketoacid
intermediate 5. These results suggest that installing two of saccharin into the oxalyl core protects
from hydrolysis and favors the CO generating reaction pathway.

Figure 2.7 Synthesis of saccharin keto acid intermediate

2.2.4

Effect of pH

The effect of pH was also studied. Since the prodrug system involves hydrolysis, low pH
might enhance the hydrolysis rates and therefore decrease CO yield. This is indeed what was
observed with prodrug BW-CO-306 wherein CO yield decreased from 60% to 30% with
decreasing pH (Fig 2.8). Interestingly, the CO release yield for prodrug BW-CO-307 is pHindependent with CO yields constant at around 90% across a broad pH range (Fig 2.8).
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Figure 2.8 Effect of pH on CO and CO2 yield in 4:1 acetonitrile:buffer (pH 1 – glycine/ NaCl/ HCl,
pH 3 – citric acid/ NaOH/ HCl, pH 7.4 – phosphate buffer) at 37 °C, incubation time =
1 h.
2.2.5

CO release kinetics

A good CO donor should be stable during storage and only release CO in physiological
conditions. RP-HPLC studies revealed that prodrugs BW-CO-306 and BW-CO-307 are stable as
a solid for at least 24 days exposed to ambient light and temperature. These prodrugs are also stable
as a solution of acetonitrile stored at room temperature for at least seven days. Kinetic experiments
using HPLC revealed that the half-lives of compound BW-CO-306 and BW-CO-307 in 60%
phosphate buffered saline is 1.28 ± 0.03 min and 9.5 ± 0.14 min, respectively.

Figure 2.9 Decomposition profile of BW-CO-306 in 60% PBS analyzed by RP-HPLC.
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Figure 2.10 Decomposition profile of BW-CO-307 in 60% PBS analyzed by RP-HPLC.

HPLC and NMR analysis both provide proof that products after CO release are mainly the
benign carriers saccharin and acesulfame.
2.2.6

Recapitulation of anti-inflammatory effects of CO

To further demonstrate that these compounds are compatible CO donors in biological
environment and that these donors can recapitulate CO-associated anti-inflammation activity, an
ELISA assay for the pro-inflammatory cytokine TNF-𝛼 was conducted (Fig 2.11). Dosedependent inhibition of LPS-induced secretion of TNF- 𝛼 was observed.
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Figure 2.11 The anti-inflammatory effects of BW-CO-306/Sac-CO in Raw 264.7 cells. Mean of
each concentration vs LPS 1ug/ml: * p<0.05, ** p<0.01 and *** p<0.001; Mean of
each concentration vs corresponding saccharin only group: # p<0.05 and ###
p<0.001
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2.2.7

Pharmacokinetic Study for BW-CO-306 (collaborator’s work)

To assess the utility of this CO donor in in vivo applications, BW-CO-306 was
administered to mouse orally through gavage and the elevation of COHb in the blood was
monitored by a CO-oximeter. Results showed that a dose-dependent elevation of COHb was
observed up to around 5.5% COHb (Fig 2.12a). Compared to BW-CO-103, one of the most
studied CO prodrug from our lab which has been shown to be efficacious in various animal models
such as colitis, BW-CO-306 achieved a higher COHb elevation (Fig 2.12b). Consistent with, in
vitro kinetic properties of BW-CO-306 and BW-CO-103, with half-lives of 1.2 min and 22 min,
respectively, BW-CO-103 gave a more sustained elevation of COHb while BW-CO-306 gave a
burst of COHb elevation that only lasted for around 30 min.

Figure 2.12 Pharmacokinetic studies for BW-CO-306. Work done by Minjia Wang and Chalet
Tan of the University of Mississippi.

2.3

Experimental Section
2.3.1

General Experimental Details

All reactions were carried out under nitrogen atmosphere using glassware that was
previously oven-dried overnight with magnetic stirring unless otherwise indicated. Unless
otherwise noted, all reagents were obtained from commercial suppliers (Sigma Aldrich, VWR
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International, and Oakwood Chemicals) and used without further purification. Thin layer
chromatography was performed on glass-backed silica gel TLC plates (250 m) using mixtures of
hexanes/ethyl acetate as eluent, and using either UV light, iodine powder, or potassium
permanganate stain for visualization. Column chromatography was done using Silica Flash P60
silica gel (230-400 mesh). 1H and 13C NMR spectra were recorded on Bruker-400 spectrometers
(400 MHz and 100 MHz, respectively). Chemical shifts were reported in ppm relative to residual
solvent peaks (7.26 for 1H, 77.1 for

13

C, CHCl3/CDCl3) and ( 2.49 for 1H, and 39.1 for

13

C,

DMSO/DMSO-d6). Data are reported as follows: bs= broad singlet, s= singlet, d= doublet, t=
triplet, q= quartet, m= multiplet, dd= doublet of doublets, ddd= doublet of doublet of doublets,
ddt= doublet of doublets of triplets, td= triplet of doublets; coupling constants in Hz; integration.
Accurate mass measurements were acquired at the Mass Spectrometry Facilities at Georgia State
University. For spectrophotometric studies, Shimadzu PharmaSpec UV-1700 was used as UV-Vis
spectrophotometer; while Shimadzu RF-5301PC fluorimeter was used for fluorescent studies.
Agilent 7820A with TCD detector was used for CO and CO2 quantification.
2.3.2

Synthesis of CO prodrugs

Compound 1:105 To a solution of saccharin (1g, 5.46 mmol) and triethylamine (766 µL, 5.46
mmol) in THF was added dropwise oxalyl chloride (190 µL, 2.73 mmol) dissolved in THF at 0
°C. After addition of oxalyl chloride, the reaction mixture was stirred at room temperature for 3 h.
Then THF was removed by rotary evaporation. The residue was re-dissolved in dichloromethane,
washed with water (2 x 10 mL), saturated NaHCO3 (3 x 10 mL), and brine. The organic layer was
then concentrated in the rotary evaporator at <30 °C to give white solid. The isolated solid was
recrystallized in acetonitrile to yield a white solid. 1H NMR (CD3CN): 8.13-8.22 (6H, m), 8.01-
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8.05 (2H, m). 13C NMR (CD3CN): 159.5, 156.8, 139.8, 139.6, 137.4, 128.4, 125.2, 123.3. HRMS
(ESI) calculated for C16H8N2O8S2 [M+Na]+: m/z, 442.9620 found 442.9626.

Compound 2: To a suspension of acesulfame K (1 g, 4.97 mmol) in THF (10 mL) stirring at 0 °C
was added dropwise oxalyl chloride (173 µL, 2.49 mmol) dissolved in THF. The reaction mixture
was stirred in ice-bath for 10 min and then stirred at room temperature for 3 h. Then, the reaction
mixture was concentrated in the rotavap. The crude residue was dissolved in DCM and washed
with water (2 x 20 mL), sat NaHCO3 (2 x 20 mL), and brine. The organic layer was dried over
Na2SO4 and concentrated in the rotavap to give a yellowish solid. The solid was recrystallized in
acetonitrile to yield a white crystalline solid. 1H NMR (CD3CN) 6.12 (m, 1H), 2.31 (m, 3H). 13C
NMR (CD3CN) 167.9, 160.8, 156.4, 104.4, 20.4. HRMS (ESI) calculated for C10H8N2O10S2
[M+Na]+: m/z 402.9518, found 402.9521.

Compound 3: To a solution of N-(methylsulfonyl)benzamide (350 mg, 1.76 mmol) and
triethylamine (247 µL, 1.76 mmol) in THF was added dropwise oxalyl chloride (61 µL, 0.88
mmol) dissolved in THF while stirring at 0 °C. After the addition, the reaction mixture was stirred
at room temperature. Then THF was removed by rotary evaporation. The residue was re-dissolved
in dichloromethane, and washed with water (2 x 10 mL), saturated NaHCO3 (3 x 10 mL), and
brine. The organic layer was then concentrated in the rotary evaporator at <30 °C to give a solid.
The isolated solid purified using silica gel column with dichloromethane as eluting solvent to give
a white solid.1H NMR (CD3CN) 8.04-8.06 (2H, m), 7.77-7.81 (1H, m), 7.58-7.62 (2H, m), 3.62
(3H, s).

13

C NMR (CD3CN) 169.2, 137, 132.9, 131.6, 130.5, 44.5. HRMS (ESI) calculated for

C18H16N2O8S2 [M+Na]+: m/z 475.0248, found 475.0249.
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Compound 4: To a solution of oxalyl chloride (1.8 mL) in diethyl ether stirring at 0 °C, was slowly
added a solution of tert-butanol (2.0 mL) dissolved in diethyl ether. The mixture was allowed to
warm to room temperature and stirred further for 20 h. Then, the mixture was concentrated in the
rotavap to give a clear, colorless liquid, which was directly used in the next step without further
purification. To a solution of saccharin (1300 mg) and triethylamine (3.0 mL) in dichloromethane
was added slowly a solution of tert-butyl 2-chloro-2-oxoacetate dissolved in dichloromethane.
After 3 h stirring, the reaction mixture was diluted with dichloromethane and then washed with
saturated NaHCO3. The organic layer was dried in the rotavap and suspended in diethyl ether. The
solid was isolated by filtration to the product. 1H NMR (CDCl3) 8.16-8.17 (1H, m), 7.94-8.06 (3H,
m), 1.62 (9H, s). 13C NMR (CDCl3) 157.1, 156.8, 156.8, 138.9, 137.3, 135.5, 126.7, 124.5, 121.7,
87.2, 27.9.
Compound 5: To a solution of compound 4 (50 mg) in dichloromethane while stirring at 0 °C was
added trifluoroacetic acid (1 mL). Then the reaction was stirred at room temperature. After 5 h,
the reaction mixture was dried in the rotary evaporator to give a white solid. 1H NMR (CD3CN)
8.04-8.06 (2H, m), 7.77-7.81 (1H, m), 7.58-7.62 (2H, m), 3.62 (3H, s). 13C NMR (CD3CN) 169.2,
137, 132.9, 131.6, 130.5, 44.5.
2.3.3

Effect of pKa of leaving group

To a solution of CO probe COP-1 (0.5 uM) in 3% DMSO in PBS, a solution of oxalyl derivative
in DMSO was added to make a final concentration of 100 uM. The resulting mixture was incubated
at 37 oC at different time points, and the fluorescence emission intensity was recorded from 490630 nm with an excitation wavelength of 475 nm.
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Figure 2.13 Fluorescent turn-on response of COP-1 against BW-CO-306
2.3.4

Qualitative CO detection: CO myoglobin assay

Direct detection of carbon monoxide release was done through a “two-compartment” MbCO assay. The set-up was assembled by putting a small vial inside a bigger vial and sealing the
system. The bigger vial contains the deoxy-Mb solution while the small vial contains the CO
prodrug. The deoxy-Mb solution was prepared by degassing a solution of myoglobin in PBS (1
mg/mL, pH = 7.4) with nitrogen for at least 30 min, and then converted to deoxy-Mb by adding
freshly prepared solution of sodium dithionite (1 mL, 22 mg/mL). Then acetonitrile was added to
the small vial to dissolve CO prodrug then PBS was added to initiate CO release. The whole setup was then incubated at 37 ° C. At the end of 1h, the set-up was cooled in an ice-bath for 10 min
to increase the solubility of CO gas, after which, the incubated solution was immediately
transferred into a cuvette for UV-Vis spectral measurements.
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Figure 2.14 Spectral changes associated with CO binding with deoxymyoglobin
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2.3.5

Quantitative CO detection: GC-TCD

An Agilent 7820A GC System equipped with a thermal conductivity detector was used to
detect and quantify CO release yield of the CO prodrugs. Using a gas tight syringe, specific
volumes of the headspace of 20-mL headspace vials were sampled and transferred to the injector
port maintained at 125 °C. Helium was used as the carrier gas with a flow rate of 30 mL/min.
Gaseous components of the headspace were separated by passing through a packed column with
60/80 Carboxen-1000 matrix support, L × O.D. × I.D. 15.0 ft (4.6 m) × 1/8 in. × 2.1 mm (Supelco).
The column was heated 35 °C for 5 min then 225 °C at 20 °C/min while the detector was held at
125 °C. Under these conditions, CO had an elution time of around 7.4 minutes while CO2 eluted
at 13.4 minutes.

Figure 2.15 Sample chromatogram for CO calibration curve (0 – 20 µmol)
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Figure 2.17 Sample chromatogram for BW-CO-306 sample

Figure 2.16 Sample chromatogram for CO2 calibration curve (0 – 20 µmol).

2.3.6

Kinetic Experiments

A 200 µL aliquot of incubated sample was placed inside a 0.5 mL vial followed by dilution with
200 µL of acetonitrile. The study was performed using the Shimadzu Prominence UFLC with a
reversed-phase analytical column (Waters C18 3.5 µM, 4.6 x 100 mm) at 25 °C. The flow rate was
set at 1 mL/min. Gradient elution using acetonitrile and deionized water with 0.05% TFA was used
to elute out the components of the sample. Elution conditions: 0-7 min 50% to 70% acetonitrile;

50
injection volume of 10 µL; detection wavelength of 254 and 280 nm. Experiments were done in
triplicates.
2.3.7

NMR Studies

Around 5 mg of prodrug was dissolved in 450 µL of deuterated acetonitrile. Then a proton
and carbon NMR were run. Then 250 µL of deuterated water was added to the NMR tube. Then a
proton and carbon NMR run were run at different time points.
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Figure 2.19 BW-CO-306 is converted mainly to saccharin as monitored by NMR.

Figure 2.18 BW-CO-307 is converted mainly to acesulfame as monitored by NMR
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2.3.8

Oxalic Acid Quantification

The LC-MS analysis was performed on an Agilent 1200 HPLC and 3200 API triple
quadrupole mass spectrometer with electrospray ionization source in a negative mode. Selected
ion mode was used for the detection of ions at m/z 182 for saccharine and m/z 89 for oxalic acid.
A 5 uL of sample solution was directly delivered to the mass spectrometer ionization source with
an Agilent autosampler and HPLC by mixing with 1%ACN in water mobile phase at 200uL/min
flow rate. No column was used. Three minutes were recorded and the peak area was integrated
and the peak are ratio of PA(Oxalic acid)/PA(Saccharin) vs Concentration ratio
(C(Saccharine)/C(Oxalic acid) was plotted as standard curve. The linear regression equation was
generated for the calculation of the ratio of unknowns.

Figure 2.20 Standard curve for LC-MS determination of oxalic acid generated from BW-CO306
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2.3.9

Cytotoxicity Assay

For the CCK-8 assay, Hela cells were cultured in DMEM (Dulbecco’s Modified Eagle’s
Medium) supplemented with 10% fetal bovine serum (MidSci; S01520HI) and 1% penicillinstreptomycin (Sigma-Aldrich; P4333) at 37 °C with 5% CO2. Fresh medium was replenished
every other day. The cells were treated with the compounds (0–100 μM) using 1% DMSO in
DMEM for 24 h.

Figure 2.21 Cytotoxicity profile of prodrug BW-CO-306 against HeLa cells
2.3.10 TNF-𝛼 determination
Anti-inflammatory effect of BW-CO-306 was tested in RAW246.7 cell by repeating
addition with 1 hour interval in 5 hours. After 5 hours, 1 ug/ml of LPS was added to the cell culture
medium and incubated for 1 hour. TNF-𝛼 concentration in the supernatant culture medium was
then determined with ELISA kit (Biolegend, USA) according to the manufacture’s protocol.

2.4

Conclusion
In summary, a new class of CO donors consisting of benign carriers was developed. The

mechanism of release is based on hydrolysis, followed by a decarboxylation and decarbonylation.
Specifically, two CO prodrugs utilizing FDA approved sweeteners, saccharin and acesulfame,
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were identified to release CO in aqueous solutions with half-lives of 1.28 ± 0.03 min and 9.5 ± 0.1
min. BW-CO-306 was demonstrated to recapitulate anti-inflammatory effects of CO in cell
studies. Furthermore, oral administration of BW-CO-306 in mice led to elevation of COHb level
of up to 5.5%.
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3

PHOTOACTIVATED CO SURROGATE STREAMLINES LIGHT-MEDIATED PdCATALYZED CARBONYLATION REACTIONS OF CHALLENGING
SUBSTRATE

3.1

Introduction
3.1.1

Carbon Monoxide as a Reagent

Transition metal-catalyzed carbonylation, pioneered by Heck and co-workers,106 is a onestep route to directly introduce molecular complexity in organic synthesis enabling access to a
wide range of carbonyl containing intermediates.107 In this field, two of the many contemporary
and practical issues are (1) the design of appropriate CO donors/surrogates for reaction without
having to use gaseous CO because of its toxicity and flammable nature108 and (2) the activation of
otherwise non-reactive site for CO “insertion.”109-111
In addressing the first issue, considerable research effort has been devoted to the
development of bench-stable, solid or liquid reagents that are able to deliver CO. These alternative
CO sources, or CO surrogates, include a wide array of compounds ranging from low molecular
weight compounds such as CO2,112 formic acid and its derivatives,108 chloroform,113 oxalyl
chloride,102 acid chlorides,114 oxalic acid,115 paraformaldehyde and methanol116,117 to more
complex compounds such as metal carbonyls,118 aldehydes,119,120 silacarboyxlic acids,121 and 9methyl-fluorene-9-carbonyl chloride,114 among many others. Indeed, these alternative CO sources
were demonstrated to provide a clear advantage over the direct use of CO gas.
In addressing the second issue, light-activation has been shown to facilitate carbonylation of
challenging substrates such as unactivated alkyl halides and bulky nucleophiles. The application
of existing CO surrogates specifically for light-mediated carbonylation involves CO generation in
a separate vessel because the reaction conditions needed are non-compatible with the subsequent
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carbonylation step (Fig 3.1a). Current approaches involve thermal activation or transition metalmediated CO release in one vessel, run in parallel with a secondary vessel where photoactivated
carbonylation takes place. Herein, we describe a “one stone, two birds” approach through the
development of a high-content CO donor, which releases CO under the same photolysis conditions
needed for carbonylation (Fig 3.1b).
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Figure 3.1 (A) Previous CO donors necessitate two-chamber reactions vessel and a different set
of reaction conditions for CO production and CO consumption for light mediated
carbonylation reactions. (B) Photo-activated CO donor simplifies reaction set-up and
protocol.

3.2

Results and Discussion
3.2.1

Design of Photo-Activated CO donor

There are many compounds capable of decarbonylation in response to light. Among those,
we are looking for a small molecule that can carry high CO load and respond to low power visible
light that are commonly used for light-assisted carbonylation reactions. Fig 3.2 shows two
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examples of compounds that can undergo photobisdecarbonylation in response to blue light.
CORM-S1, an Fe containing organometallic compound, is easily synthesized in one step from
readily available starting materials. However, the transition metal center and the nucleophilic
photoproduct cysteamine can potentially interfere with the carbonylation reaction. Similarly, DK1,
an aromatic 1,2-diketone, also releases two equivalents of CO upon exposure to visible light.
Unlike CORM-S1, the photoproducts are not expected to interfere with the carbonylation reaction.
However, DK1 and its derivatives require multi-step synthesis involving the use of autoclave, high
temperature, and long reaction times.
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Figure 3.2 Examples of CO donors releasing two equivalents of CO

58
Considering the pros and cons of CORM-S1 and DK1, we designed a class of photoactivated CO donor having the advantages of each donor. With the potential interference brought
by a introducing another transition metal to the reaction mixture, we sought to construct an organic
donor similar to DK1 but without the aromatic rings and with a simpler synthetic procedure.
Starting from the readily available 2,3-dihydroxybenzoic acid, we prepared the aliphatic bridged
1,2-diketone, BW-CO-401 and BW-CO-402, through amidation followed by a cascade oxidation
and intramolecular Diels Alder (Fig 3.3). Through amidation, an alkyne is installed proximal to
the latent quinone group formed after oxidation of the catechol moiety. The diene of the
benzoquinone reacts via a Diels-Alder reaction with the tethered alkyne. The reaction parallels that
of the fast cycloaddtion between 1,2-quinones and strained alkynes to form unsaturated diketone
compounds as stable products.122 Consistent with our earlier findings,75,123 tethering a regular
alkyne intramolecular to the benzoquinone obviated the need for a strained alkyne to drive the
Diels-Alder reaction.

Figure 3.3 Design of visible-light activated CO donor releasing two equivalents of CO
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3.2.2

CO release, yield, kinetics

The UV-Vis spectrum of BW-CO-401 shows two absorption bands. The absorption
between 420 to 500 nm with λmax of 441 nm corresponds to the n-𝜋* transition of the carbonyl
groups. Irradiation of CO-401 for 5 minutes with a blue LED (440-445 nm) led to the gradual
disappearance of the absorption at this wavelength (Fig 3.4a). Under ambient light, BW-CO-401
remains stable (Fig 3.4b). NMR analysis confirms the conversion of BW-CO-401 to photoproduct
2 in a quantitative manner (Fig 3.5). After irradiation for 15 min, the alkene protons were converted
to aromatic protons accompanied by the disappearance of the diastereotopic methylene protons.
The disappearance of two carbonyl carbons and the shift of aliphatic sp2 and sp3 carbon peaks to
the aromatic region were all consistent with the expulsion of two equivalents of CO driven by
aromatization. Furthermore, GC-TCD headspace analysis of BW-CO-401 confirmed unloading
of two equivalents of CO (27 mol% CO) (Fig 3.6) upon exposure to blue LED in a range of
solvents including dimethylsulfoxide, dimethylacetamide, and acetonitrile.
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Figure 3.4 (A) UV-Vis spectrum BW-CO-401 (1mM in DMSO) upon exposure to blue LED light.
(B) BW-CO-401 is stable under ambient light but releases CO when exposed to blue
LED.
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BW-CO-402, on the other hand, was found to be unstable under ambient irradiation.
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Figure 3.6 CO yield from BW-CO-401 in DMSO and in aqueous solutions
In aqueous systems, 1,2-diketones are readily and reversibly hydrated.124 Liao and coworkers reported that hydration prevents 1,2-diketones from releasing CO, and that micellar
structures67 and hydrophobic moieties such as tert-butyl groups125 can circumvent the hydration
problem. BW-CO-401 also undergoes hydration. However, instead of abolishing its CO releasing
capability, hydration merely slows down the process. Fig 3.7 shows that the diketone n-𝜋*
transition at 441 nm present in DMSO disappears in the presence of water while another peak
appears at ≈380 nm. This suggests that one of the carbonyl groups is hydrated leaving one ketone
group intact.
3.5

dmso:water 1:1
3

dmso

Absorbance

2.5

2

1.5

1

0.5

0
250

350

450

550

wavelength (nm)

Figure 3.7 UV-Vis Spectra of BW-CO-401 in DMSO and DMSO:water 1:1
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NMR studies reveal that the hydration equilibrium favors the hydrated form in DMSO:water
solutions. Upon extended irradiation with LED (440-445 nm) for around 65 min, the hydrated
products were converted to compounds with spectra corresponding to that of by-product 2.
Reversibility of the hydration was further confirmed when resuspension in DMSO of a lyophilized
1:1 DMSO-d6:D2O solution gave an NMR spectra corresponding to that of intact BW-CO-401.
CO yield is also dependent on water ratio. At 50% DMSO, only 0.8 eq of CO was recovered after
5 minutes of irradiation. Increasing the irradiation time to 30 min increased CO recovery up to 1.5
eq. Further increase in water content up to 2% DMSO led to a yield of 1.2 eq of CO (Fig 3.6) after
irradiation for 30 min. These findings indicate that these 1,2-diketones are compatible with
applications in aqueous systems. Nevertheless, irradiation time of BW-CO-401 will need to be
adjusted accordingly to achieve maximal CO yield.
3.2.3

Proof-of-Concept: CO Surrogate for general carbonylation reactions

Due to the vicinal carbonyl moieties, 1,2-diketones such as BW-CO-401 are rendered more
susceptible to attack by nucleophiles. Because of the this, physical separation of the CO generating
reaction from the carbonylation reaction may be necessary. The use of commercially available
two-chamber gas reactors have been shown to be effective in employing most of the CO
surrogates.126 But because CO generation is light-activated, we were able to develop a protocol
allowing the use of BW-CO-401 in one-pot systems. Instead of spatial separation, we utilize light
as an external trigger to temporally enrich the reaction vessel with CO from BW-CO-401 before
the addition of reaction components that may inactivate the donor.

63
We assessed the utility of BW-CO-401 in a one-pot system in Pd-catalyzed carbonylative
amidation under different reaction conditions (Fig 3.8). Indeed, we find that temporal separation
of the CO generation process and the carbonylation reaction allowed the use of BW-CO-401 under
varying reaction conditions involving different bases, solvents, and temperature. Because BWCO-401 releases two equivalents of CO, substoichiometric amount (0.75 eq) of the donor is
needed to provide 1.5 eq of CO to the reaction mixture. The low-power visible light needed for
the reaction coupled with the fast kinetics (Fig 3.4) associated with the photo-bisdecarbonylation
of BW-CO-401 provided ample amount of CO within 30 minutes of irradiation without instigating
possible cross photoreaction of 1,2-diketones127 with other components of the reaction mixture.
Results also indicate that photoproduct 2 is a stable, benign by-stander that does not interfere with
the carbonylation process.

Figure 3.8 BW-CO-401 as a CO surrogate in a conventional carbonylation reaction
employing different reaction condition.

3.2.4

CO donor streamlines light-assisted carbonylation of non-activated alkyl

halides and bulky nucleophiles
Carbonylation of alkyl halides is challenging due to its inherent slow oxidative addition step
coupled with increased propensity to undergo isomerization via β-elimination.128 Through a radical
reaction pathway, previously challenging substrates such as non-activated alkyl halides and bulky
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nucleophiles have been made more accessible for carbonylation reactions.109-111 Since the
conditions needed to activate reported CO surrogates are incompatible with the conditions used
for light-mediated carbonylation, two-chamber vessels were previously necessitated to
accommodate the different reaction conditions for CO generation and carbonylation.109,111 Here
we show that recruitment of light to initiate generation of CO from BW-CO-401 streamlined lightmediated carbonylation reactions by doing away with CO gas tanks and allowing simplified onepot reaction set-up. Cyclohexyl iodide was carbonylated at ambient temperature (Fig 3.9a).
However, only trace amounts of the product were detected when cyclohexyl bromide was used as
substrate. Carbonylation with the bulky nucleophile 2,6-diisopropylaniline was also shown to be
compatible with developed CO donor and protocol (Fig 3.9b).

Figure 3.9 BW-CO-401 as a light activated CO donor in carbonylation of challenging substrates
– (a) non-activated alkyl halide, and (b) bulky nucleophile

65
3.2.5

Immobilization on a resin

Using BW-CO-401 in a one-pot system has several limitations – (1) lower CO yield due to
hydration when reaction is done in aqueous system, and (2) in specific instances, desired product
may have similar chromatographic properties to the by-product making purification more
challenging. While these can be easily addressed by employing two-chamber techniques,
immobilization of the 1,2-diketone scaffold to a polymeric resin can be an alternative solution.
Immobilization to a hydrophobic resin (BW-CO-403) protects the diketone from hydration and
allows removal of photoproduct by simple filtration. We demonstrate its utility in two reactions
wherein immobilization improved the yield for carbonylation in aqueous system and also
simplified the work-up and purification of a specific carbonylation reaction wherein the product

Figure 3.10 Immobilization to a polymeric resin solves two inherent limitations - protection of
1,2-diketone moiety against nucleophiles and removal of photoproduct by filtration
for easy work-up.
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co-elutes with by-product 2 (Fig 3.10). Immobilization also expanded the utility of this class of
CO donors to include biological applications.
3.3

Experimental Section
3.3.1

General Experimental Details

All reagents and solvents were used as is without further purification. Starting materials
and solvents were purchased from Sigma Aldrich, VWR International, and Oakwood Chemicals.
Analytical-grade solvents were used for all reactions except for moisture-sensitive reactions in
which anhydrous solvents were used. Thin layer chromatography was performed on glass-backed
silica gel TLC plates (250 m) using mixtures of hexanes/ethyl acetate as eluent, and using either
UV light, iodine powder, or potassium permanganate stain for visualization. Column
chromatography was done using Silica Flash P60 silica gel (230-400 mesh). 1H and

13

C NMR

spectra were recorded on Bruker-400 spectrometers (400 MHz and 100 MHz, respectively).
Chemical shifts were reported in ppm relative to residual solvent peaks (7.26 for 1H, 77.1 for 13C,
CHCl3/CDCl3) and ( 2.49 for 1H, and 39.1 for

13

C, DMSO/DMSO-d6). Data are reported as

follows: bs= broad singlet, s= singlet, d= doublet, t= triplet, q= quartet, m= multiplet, dd= doublet
of doublets, ddd= doublet of doublet of doublets, ddt= doublet of doublets of triplets, td= triplet of
doublets; coupling constants in Hz; integration. Accurate mass measurements were acquired at the
Mass Spectrometry Facilities at Georgia State University. For spectrophotometric studies, Varian
Cary 100-Bio was used as UV-Vis spectrophotometer. Agilent 7820A with TCD detector was used
for CO quantification.
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3.3.2

Synthesis of CO donors

Figure 3.11 Synthesis of BW-CO-401
Intermediate 3129: To a solution of 2,3-dihydroxybenzoic acid (340 mg, 2.2 mmol) in acetic
anhydride (650 𝜇L, 6.8 mmol) was added five drops of H2SO4. The reaction mixture was heated
under reflux for 2 h. After cooling to room temperature, iced water was added, and the reaction
was stirred for a few minutes. The precipitate was filtered to give an off-white solid (323 mg,
95%). 1H NMR (400 MHz, CDCl3) 7.99 (1H, dd), 7.44 (1H, m), 7.36 (1H, t), 2.34 (3H, s), 2.33
(3H, s). 13C NMR (100 MHz, CDCl3) 169.2, 168.6, 168.4, 143.8, 143.3, 129.7, 129.0, 126.4, 124.0,
20.7. HRMS (ESI) calculated for C11H10O6 [M+Na]+: m/z 261.0375, found 261.0368.

Intermediate 4: To a solution of 3 (304 mg, 1.3 mmol) in anhydrous DCM was added oxalyl
chloride (240 𝜇L, 2.8 mmol) followed by DMF (3 drops). The reaction mixture was stirred at room
temperature. Gas evolution was observed. After 1 h, the solvent was removed in vacuo, then the
crude acid chloride was redissolved in DCM while cooling in an ice-water bath. Triethylamine
(400 𝜇L, 2.0 mmol) was added dropwise followed by the addition of the N-methylpropargylamine
(130 𝜇L, 1.2 mmol) dropwise. The reaction mixture was removed from ice-bath and allowed to
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run at room temperature for 1.5 h. The solvent was removed in vacuo and the crude product was
loaded into a column and eluted using DCM. The isolated compound was dissolved in ammonia
in ethanol (2.0 M, 4.8 mL, 9.6 mmol) and stirred overnight. The mixture was concentrated in under
rotary evaporation and loaded into a silica gel column using hexane: ethyl acetate to give a white
solid (256 mg, 75% over three steps). 1H NMR (400 MHz, CDCl3) 6.97-6.94 (2H, m), 6.76 (1H,
t, J = 7.9 Hz), 4.26 (2H, d), 3.20 (3H, s), 2.36 (1H, t). 13C NMR (100 MHz, CDCl3) 171.6, 146.0,
145.9, 119.3, 119.2, 117.8, 117.4, 78.1, 73.2, 60.5, 21.1. HRMS (ESI) calculated for C11H11NO3
[M+Na]+: m/z 228.0637, found 228.0640.

BW-CO-401: To 4 (300 mg, 1.5 mmol) dissolved in diethyl ether was added o-chloranil (378 mg,
1.5 mmol) while stirring at -78 °C for 30 min. Then the reaction mixture was removed from the
dry ice-acetone bath and stirred at room temperature. After 30 min, ether was removed through
rotary evaporation and residue was loaded into a column and eluted using hexane: ethyl acetate to
give a bright yellow solid (144 mg, 48%). CO-401: 1H NMR (400 MHz, DMSO-d6) 6.65-6.72
(2H, m), 6.38-6.40 (1H, m), 4.11-4.33 (3H, m), 2.89 (3H, s).

13

C NMR (100 MHz, DMSO-d6)

180.6, 176.4, 166.8, 140.9, 131.3, 130.8, 121.2, 67.7, 52.0, 50.8, 29.9. HRMS (ESI) calculated for
C11H9NO3 [M+Na]+: m/z 226.0480, found 226.0488.

Figure 3.12 Alternative Procedure to Intermediate 4
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2,3-Dihydroxybenzoic acid (2 g, 13 mmol) was suspended in SOCl2 (8 mL, 110 mmol) then
refluxed for 3 h. After cooling to room temperature, reaction mixture was concentrated by rotary
evaporation to give a slight yellow solid. The crude product was dissolved in DCM followed by
slow addition of triethylamine (2.8 mL, 20 mmol) and N-methylpropargylamine (1.6 mL, 19.2
mmol). After overnight stirring, reaction mixture was concentrated in the rotary evaporator to give
a sticky yellow residue. Residue was redissolved in dichloromethane, washed with 1M HCl and
brine, and concentrated in the rotary evaporator. The residue was loaded into a column using
dichloromethane: ethyl acetate as eluent (1.09 mg, 41%). 1H NMR same as above.

3.3.3

Conversion of CO-401 to photoproduct 2

Figure 3.13 Conversion of BW-CO-401 to photoproduct 2

BW-CO-401 (52.3 mg, 0.26 mmol) was dissolved in acetonitrile and exposed to blue LED
for 1 h. The solution gradually turned from bright yellow to colorless. After completion of reaction
based on TLC, the reaction mixture was concentrated in the rotary evaporator, loaded into a
column, and eluted using dichloromethane: ethyl acetate to give a white solid (37.6 mg, 99%). 1H
NMR (400 MHz, ACN-d3) 7.68 (1H, d, J = 7.5 Hz), 7.58-7.51 (2H, m), 7.46 (1H, t, J = 7.8 Hz),
4.38 (2H, s), 3.10 (3H, s). 13C NMR (100 MHz, ACN-d3) 168.8, 142.9, 133.9, 132.0, 128.7, 124.0,
123.6, 52.5, 29.4. HRMS (ESI) calculated for C9H9NO10 [M+Na]+: m/z 170.0582, found 170.0587.
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3.3.4

Synthesis of Immobilized Donors

Figure 3.14 Preparation of immobilized version of CO donor

Intermediate 5: 6-Aminohexanoic acid (3 g, 22.9 mmol), and SOCl2 (17 mL, 234 mmol) were
stirred at room temperature for 2 h, followed by concentration in the rotary evaporator. Then,
NaHCO3 suspended in tert-butanol was added slowly and the resulting suspension was stirred at
room temperature overnight. Solvent was removed and the residue was dissolved in ethyl acetate
and washed with 1.0 M NaOH (3x). The organic layer was washed with water and brine to give a
yellow liquid (13.4 g, 93%). 1H NMR (400 MHz, CDCl3) 2.39 (2H, t, J = 8.0 Hz), 1.91 (2H, t, J =

71
8.0 Hz), 1.32-1.26 (2H, m), 1.18-1.05 (15H, m) 13C NMR (100 MHz, CDCl3) 172.5, 79.34, 41.5,
35.0, 32.9, 27.6, 25.9, 24.5. HRMS (ESI) calculated for C10H21NO2 [M+H]+: m/z 188.1651, found
188.1656.

Intermediate 6: To neat intermediate 5 (473 mg, 2.5 mmol) was added propargyl bromide (50
mg, 0.42 mmol). Reaction mixture was stirred at room temperature overnight. Then reaction
mixture was loaded into a column and eluted using dichloromethane: ethyl acetate to give a lightyellow oil (86 mg, 90%). 1H NMR (400 MHz, CDCl3) 3.51 (2H, J = 2.4 Hz), 2.63 (2H, t, J = 8.0
Hz), 2.18-2.14 (3H, m), 1.55 (2H, qt, J = ), 1.45 (2H, qt, J = ), 1.39 (9H, s), 1.31 (2H, m), 1.19
(1H, s). 13C NMR (100 MHz, CDCl3) 173.1, 82.3, 80.0, 71.3, 48.5, 38.2, 35.5, 29.5, 28.2, 26.8,
25.0. HRMS (ESI) calculated for C13H23NO2 [M+Na]+: m/z 248.1626, found 248.1628.

Intermediate 7: To a solution of 3 (2.1 g, 8.8 mmol) in anhydrous DCM was added oxalyl chloride
(1.3 mL, 15.2 mmol) followed by DMF (4 drops). The reaction mixture was stirred at room
temperature. Gas evolution was observed. After 2 h, the solvent was removed in vacuo, then the
crude acid chloride was redissolved in DCM while cooling in an ice-water bath. Triethylamine
(1.9 mL, 13.7 mmol) was added dropwise followed by the addition of 6 (2.0 g, 8.9 mmol) dropwise.
The reaction mixture was removed from ice-bath and allowed to run at room temperature for 1.5
h. The solvent was removed in vacuo and the crude product was loaded into a column and eluted
using DCM. The isolated compound was dissolved in trifluoroacetic acid and stirred at room
temperature for 2 h. The mixture was concentrated in the rotavap and loaded into a column using
hexane:ethyl acetate to give a white solid (2.1 g, 61% over three steps). Mixture of regioisomers:
1

H NMR (400 MHz, CDCl3) 7.34-7.16 (3H, m), 3.94-3.57 (2H, m), 3.27 (1H, t, J = 7.4 Hz), 2.38-
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2.33 (1H, m), 2.30-2.18 (8H, m), 1.71-1.64 (2H, m), 1.56-1.50 (2H, m), 1.42-1.49 (1H, m), 1.231.66 (2H, m). 13C NMR (100 MHz, CDCl3) 179.0, 178.8, 168.1, 167.7, 166.9, 166.9, 143.1, 143.0,
139.3, 139.0, 131.2, 131.2, 126.9, 126.6, 124.7, 124.6, 124.6, 124.5, 78.7, 78.6, 73.0, 72.0, 47.0,
44.8, 39.0, 33.9, 33.7, 33.4, 27.6, 26.5, 26.3, 25.9, 24.5, 24.1, 20.8, 20.8, 20.5, 20.3. HRMS (ESI)
calculated for C20H23NO7 [M+Na]+: m/z 412,1372 found 412.1367.

Loading the resin with 7:
In a microwave vessel, aminomethyl polysytrene resin (1.23 g, 2 mmol/g) was allowed to swell in
DCM and then DMF. In a separate vial, 7 (2.1 g, 5.39 mmol) and HATU (2.05 g, 5.39 mmol) were
dissolved in DMF and chilled in an ice-bath followed by addition of diisopropylethylamine (1.88
mL, 10.78 mmol). This solution was poured to the swelled resin and exposed to microwave for 5
min (T = 75 °C, P = 100 W) under nitrogen bubbling. Reaction progress was monitored using
ninhydrin-Kaiser test. Solvent was removed under vacuum and the resin was washed with DMF
and DCM.

Deprotection of catechol - ammonolysis:
Loaded resin from previous step was allowed to swell in THF then THF was removed by vacuum
followed by addition of NH3 in ethanol (40 mL) + THF (20 mL). The mixture was put in a shaker
overnight. Then solvent was removed by vacuum and resin was washed with methanol and diethyl
ether. Resin was thoroughly dried in high vacuum. Completion of reaction was followed by FeCl3
test and IR Spectroscopy.
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Tandem oxidation of catechol and intramolecular Diels Alder reaction:
Resin was swelled in DCM for a few minutes and then o-chloranil (632 mg, 2.6 mmol) was added
while in dry-ice acetone bath. The reaction mixture was allowed to sit in the bath for 1 h with
intermittent shaking. After 1 h, the reaction was shaken at room temperature for 30 min. After
which, solvent was removed through vacuum and resin was washed with DCM and ether
alternately.
After thorough drying, a 5-mg sample of the final immobilized product in a GC headspace vial
was suspended in DMSO (0.5 mL), and then exposed to blue LED (3 cm). CO concentration in
the headspace was quantified by gas chromatography and loading degree was calculated to be 1.25
mmol CO/g resin.

3.3.5

CO release yield

An Agilent 7820A GC System equipped with a thermal conductivity detector was used to
detect and quantify CO release yield of the CO prodrugs. Using a gas tight syringe, specific
volumes of the headspace of 6-mL headspace vials were sampled and transferred to the injector
port maintained at 125 °C. Helium was used as the carrier gas with a flow rate of 30 mL/min.
Gaseous components of the headspace were separated by passing through a packed column with
60/80 Carboxen-1000 matrix support, L × O.D. × I.D. 15.0 ft (4.6 m) × 1/8 in. × 2.1 mm (Supelco).
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Figure 3.15 Calibration curve for the quantification
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The column was heated 35 °C for 5 min then 225 °C at 20 °C/min while the detector was held at
125 °C. Under these conditions, CO had an elution time of around 7.4 minutes.

3.3.6

NMR and Hydration studies

NMR studies were employed to characterize the product after CO release as well as to
determine the effect of water on the CO prodrug. Around 5 mg of BW-CO-401 was dissolved in
the specified solvent (DMSO, acetonitrile, D2O) and the NMR tube was exposed to blue LED
1

(440-445 nm) for a specified time.
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Hydrated compound is converted to aromatic by product upon extended irradiation with LED (440-445 nm)

65 min incubation,
LED (440-445 nm)

35 min incubation,
LED (440-445 nm)

20 min incubation,
ambient light

5 min incubation,
ambient light

Hydrated compound is converted to aromatic by product upon extended irradiation with LED (440-445 nm)

65 min incubation,
LED (440-445 nm)
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LED (440-445 nm)

20 min incubation,
ambient light

5 min incubation,
ambient light

Figure 3.17 1H and 13C NMR spectra of BW-CO-401 in DMSO-d6-D2O upon irradiation of LED
(440-445 nm) at different time points.
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NMR of a lyophilized sample of dmso:d2o mixture reveals intact prodrug.

Figure 3.18 1H and 13C NMR spectra of a reconstituted lyophilized DMSO-d6-D2O mixture
incubated overnight.

3.3.7

General Carbonylation Reaction

General Protocol for One-pot Carbonylation:
Alkyl/aryl halide, Pd source, ligand, and CO donor are weighed into a crimp top vial and sealed
using aluminum septum caps. Air inside the vial is removed by vacuum and replaced with N2 via
a balloon, done three times. Non-nucleophilic solvent is added and N2 balloon is removed. Vial is
exposed to blue LED for 30 min at 3 cm distance. Remaining reagents (nucleophile, base, and
nucleophilic solvent) are added directly or dissolved in additional solvent through a syringe. Then,
reaction is allowed to proceed.
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Figure 3.19 Example of a reaction set-up using LED bulbs in one-pot system

General Carbonylative Amidation under different reaction condition
Reaction Condition 1(Fig 4.B.1):
4-methoxyiodobenzene (26.6 mg, 0.11 mmol), Pd(dba)2 (3.8 mg, 6.6 𝜇mol), PPH3 (16.2 mg, 14.9
𝜇mol), CO-401(16.2 mg, 0.08 mmol) were weighed into a crimp top vial and sealed. After
evacuation of air and replacement with N2, anhydrous dioxane was added (0.5 mL). Then vial was
exposed to blue LED for 30 min at 3 cm distance. Then, 6-aminohexane (0.03 mL, 0.23 mmol),
and triethylamine (0.03 mL, 0.21 mmol) were added, and the reaction mixture stirred at 80 °C
overnight. Dioxane was removed by rotary evaporation and the residue was loaded into a column
and eluted using hexane: ethyl acetate to give a faintly yellow solid (23.8 mg, 89%). 1H and 13C
NMR same as literature value.

Reaction condition 2 (Fig 4.B.2):
4-methoxyiodobenzene (26.4 mg, 0.11 mmol), Pd(PPH3)4 (7.7 mg, 6.6 𝜇mol), CO-401(16.4 mg,
0.081 mmol) were weighed into a crimp top vial and sealed. After evacuation of air and
replacement with N2, 2-methyltetrahydrofuran was added (0.3 mL). Then vial was exposed to blue
LED for 30 min at 3 cm distance. Then, 6-aminohexane (0.05 mL, 0.38 mmol), and K2CO3 (15
mg, 0.11 mmol) dissolved in deionized water (0.2 mL) were added, and the reaction mixture stirred
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at room temperature overnight under continuous blue LED irradiation. Solvent was removed by
rotary evaporation and the residue was loaded into a column and eluted using hexane: ethyl acetate
to give a faintly yellow solid (21.6 mg, 82%). 1H and 13C NMR same as literature value.

Carbonylative amidation for challenging substrates:
Non-activated Alkyl halide:
Iodohexane (30.2 mg, 0.14 mmol), Pd(PPH3)4 (7.9 mg, 6.8 𝜇mol), CO-401(21.5 mg, 0.11 mmol)
were weighed into a crimp top vial and sealed. After evacuation of air and replacement with N2,
2-methyltetrahydrofuran was added (0.3 mL). Then vial was exposed to blue LED for 30 min at 3
cm distance. Then, 6-aminohexane (0.05 mL, 0.38 mmol), and K2CO3 (15 mg, 0.11 mmol)
dissolved in deionized water (0.2 mL) were added, and the reaction mixture stirred at room
temperature overnight under continuous blue LED irradiation. Solvent was removed by rotary
evaporation and the residue was loaded into a column and eluted using hexane: ethyl acetate to
give a white solid (17.8 mg, 58%). 1H and 13C NMR same as literature value.

Iodocyclohexane (123.8 mg, 0.59 mmol), Pd(PPH3)4 (40.1 mg, 35 𝜇mol), CO-401(93 mg, 0.45
mmol) were weighed into a crimp top vial and sealed. After evacuation of air and replacement
with N2, 2-methyltetrahydrofuran was added (2 mL). Then vial was exposed to blue LED for 30
min at 3 cm distance. Then, aminocyclohexane (0.1 mL, 0.92 mmol), and K2CO3 (84 mg, 0.61
mmol) dissolved in deionized water (1 mL) were added, and the reaction mixture stirred at room
temperature overnight under continuous blue LED irradiation. Solvent was removed by rotary
evaporation and the residue was loaded into a column and eluted using hexane: ethyl acetate to
give a white solid (49.7 mg, 40%). 1H and 13C NMR same as literature.
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Bulky Nucleophile:
2-Iodotoluene (16.9 mg, 0.08 mmol), [Pd(allyl)Cl2]2 (4.6 mg, 13 𝜇mol), Bis[(2diphenylphosphino)phenyl] ether, DPE-Phos (7.4 mg, 14 𝜇mol), CO-401(21.3 mg, 0.10 mmol),
tetrabutylammonium chloride, Bu4NCl (21.7 mg, 78 𝜇mol), and benzyl benzoate (8.8 mg, 41
𝜇mol) were weighed into a crimp top vial and sealed. After evacuation of air and replacement with
N2, C6D6 was added (0.5 mL). Then vial was exposed to blue LED for 30 min at 3 cm distance.
Then, 2,6-di-tert-butylaniline (0.02 mL, 0.11 mmol), and collidine (0.02 mL, 0.15 mmol) were
added, and the reaction mixture stirred at room temperature overnight under continuous blue LED
irradiation. NMR yield was calculated based on 2-iodotoluene as limiting reactant and benzyl
benzoate as standard.

CO-403 to address hydration and purification issues:
Carbonylative Sonogashira in water:
Using BW-CO-401: 4-methoxyiodobenzene (30.2 mg, 0.13 mmol), PdCl2(PPH3)2 (4.7 mg, 6.4
𝜇mol), BW-CO-401 (20.1 mg, 0.10 mmol) were weighed into a crimp top vial and sealed. After
evacuation of air and replacement with N2, water was added (1 mL). Then vial was exposed to
blue LED for 30 min at 3 cm distance. Then, hexyne (0.02 mL, 0.19 mmol), and triethylamine
(0.05 mL, 0.14 mmol) were added, and the reaction mixture stirred at room temperature overnight.
Solvent was removed by rotary evaporation and the residue was loaded into a column and eluted
using hexane: ethyl acetate to give a faintly yellow oil (21.6 mg, 69%). 1H and 13C NMR same as
literature value.
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Using BW-CO-402: 4-methoxyiodobenzene (30.1 mg, 0.13 mmol), PdCl2(PPH3)2 (4.5 mg, 6.4
𝜇mol), BW-CO-402 (114.2 mg, 0.14 mmol) were weighed into a crimp top vial and sealed. After
evacuation of air and replacement with N2, water was added (1 mL). Then vial was exposed to
blue LED for 30 min at 3 cm distance. Then, hexyne (0.02 mL, 0.19 mmol), and triethylamine
(0.05 mg, 0.14 mmol) were added, and the reaction mixture stirred at room temperature overnight.
Solvent was removed by rotary evaporation and the residue was loaded into a column and eluted
using hexane: ethyl acetate to give a faintly yellow oil (22.1 mg, 80%). 1H and 13C NMR same as
literature value.

3.4

Conclusion
In summary, a photoactivated CO donor BW-CO-401 that can deliver two equivalents of

CO upon activation by low power visible light was developed. To the best of our knowledge, this
is the first CO surrogate of its kind that has been demonstrated to be useful under different
carbonylation reaction conditions. The use of light as a remote trigger for CO release provided
ways to simplify the protocol for carbonylation. Because CO release activation is remote and does
not require additional reaction conditions and reagents, BW-CO-401 becomes a natural choice of
CO donor for light-assisted carbonylation reactions.
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Appendix A Spectra of Compounds For Chapter 1
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Appendix B Spectra of Compounds For Chapter 2
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Appendix C Spectra of Compounds For Chapter 3
Intermediate 3
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